Pharmaceutical compositions for the treatment of allergic diseases

MYPI2025000777A0Undetermined Publication Date: 2024-02-02KINKI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000777
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-12
Filing Date
2023-08-01
Publication Date
2024-02-02

AI Technical Summary

Technical Problem

Current treatments for allergic diseases, such as bronchial asthma and atopic dermatitis, often rely on intravenous administration of antibodies, which are burdensome for patients and may require high doses of mangiferin for oral administration, necessitating more effective therapeutic agents that can inhibit NF-κB-induced kinase (NIK) activity orally.

Method used

A pharmaceutical composition comprising mangiferin, mangiferin 8a, noratiol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin, which inhibit NIK activity, effectively suppressing BAFF-induced activation of NF-κB and B cell differentiation, and can be administered orally or as processed foods, providing a lighter burden for patients.

Benefits of technology

The composition significantly reduces symptoms of allergic diseases like allergic rhinitis, atopic dermatitis, and bronchial asthma by inhibiting NIK activity, suppressing cytokine overexpression, and promoting Treg cell activation, offering a more convenient and effective treatment option compared to existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025000777_DRAWING_001
    Figure PI2025000777_DRAWING_001
  • Figure PI2025000777_DRAWING_002
    Figure PI2025000777_DRAWING_002
  • Figure PI2025000777_DRAWING_003
    Figure PI2025000777_DRAWING_003
Patent Text Reader

Abstract

Antibody drugs have been proposed to treat allergic diseases, but the route of administration is limited to intravenous route, which is inconvenient for patients. In addition, novel agents that inhibit kinases such as NIK are always needed to develop effective drugs and other products to treat allergic diseases. At least one compound selected from mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)) having a xanthone structure can improve allergic diseases and can be effective when taken orally. [Chemical compound 200] [Chemical compound 201] [Chemical compound 202] [Chemical compound 203] [Chemical compound 204] [Chemical compound 205] [Chemical compound 206] Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for improving allergic diseases

[0001] The present invention relates to compounds that inhibit NF-κB-inducing kinase (also known as NIK-MAP3K14), and these compounds are useful for the treatment and / or prevention of allergic diseases such as bronchial asthma, atopic dermatitis, allergic rhinitis such as hay fever, allergic conjunctivitis, and food allergies.

[0002] The present invention also relates to compositions, pharmaceutical compositions, and processed foods using the compounds for the prevention and treatment of allergic diseases accompanied by activation of immune cells such as B cells, Th1 cells, Th2 cells, Th17 cells, and macrophages, regulation of Treg cells that are responsible for immunosuppression, and overexpression of cytokines such as B cell activating factor (BAFF), interferon γ (IFNγ), interleukin 3 (IL-3), IL-4, IL-5, IL-6, IL-13, IL-17, and tumor necrosis factor α (TNFα).

[0003] NF-κB (Nuclear factor kappa B) is a transcription factor that regulates the expression of various genes involved in immune responses, cell proliferation, apoptosis, and carcinogenesis. NF-κB consists of five members: (1) NF-κBp65 (p65), (2) RelB, (3) c-Rel, (4) NF-κB1 (which exists as both precursor p105 and cleaved p50), and (5) NF-κB2 (which exists as both precursor p100 and cleaved p52).

[0004] NF-κB1 (truncated p50; NF-κBp50) and p65 form heterodimers, while NF-κB2 (truncated p52; NF-κBp52) and RelB form heterodimers. Activation of these NF-κB heterodimers is a signal transduction pathway that is tightly regulated by a series of events including phosphorylation and proteolysis, and is classified into two pathways: canonical and non-canonical.

[0005] NF-κB inducing kinase (NIK) is a serine / threonine kinase that plays a role in both canonical and non-canonical pathways, but is essential in the non-canonical signaling pathway. NIK phosphorylates IκB kinase α (IKKα), partially degrading NF-κBp100 and liberating NF-κBp52. NF-κBp52 forms a heterodimer with RelB, translocating to the nucleus and inducing gene expression. Furthermore, in the canonical pathway, NIK activates the IKKα, IKKβ, and IKKγ complex to form a heterodimer with p65 and NF-κBp50, which translocates to the nucleus and regulates gene expression.

[0006] The non-canonical pathway is activated by ligands such as BAFF, CD40 ligand, and lymphotoxin β receptor ligand, and NIK has been shown to be important in activating these signaling pathways. Due to its important role, NIK expression is tightly regulated.

[0007] Under normal non-stimulating conditions, NIK is degraded through interaction between NIK and TNF receptor associated factors (TRAFs), which are ubiquitin ligases, and therefore the amount of NIK protein in cells is low.

[0008] It is believed that when the non-canonical pathway is stimulated by a ligand, the activated receptor dissociates the TRAF-NIK complex, thereby increasing the concentration of NIK (Non-Patent Document 1).

[0009] BAFF is produced and secreted by T cells, monocytes / macrophages, dendritic cells, etc., and is known to regulate the differentiation, activation, survival, etc. of B cells via three types of receptors on B cells (Non-Patent Document 2).

[0010] Known receptors for BAFF include BAFF-R (BAFF-Receptor), TACI (Transmembrane activator, calcium modulator, and cyclophilin ligand and interactor), and BCMA (B cell maturation antigen).

[0011] BAFF-R and BCMA are primarily expressed in B cells, while TACI is expressed in B cells and activated T cells. BAFF-R is also expressed in T cells and macrophages. The interaction between BAFF and BAFF-R activates the NIK-mediated signaling pathway, which is essential for the formation and maintenance of B cells, which in turn synthesize immunoglobulins in response to invasion by foreign substances. BAFF also induces the differentiation and activation of T cells via BAFF-R. Furthermore, BAFF promotes the maintenance and activation of macrophages.

[0012] An appropriate level of BAFF in a patient helps maintain a normal level of immunity, but low expression can lead to immunodeficiency, and overexpression can result in abnormally high antibody production and excessive immune responses. Furthermore, when a patient exhibits allergic diseases, they exhibit activation of B cells, Th1 cells, Th2 cells, Th17 cells, and macrophages, suppression of Treg cells, and overexpression of cytokines such as BAFF, IFNγ, IL-3, IL-4, IL-5, IL-6, IL-13, IL-17, and TNFα.

[0013] When a patient shows allergies, an excessive immune response occurs against foreign antigens, resulting in the production of antibodies such as IgE. As used herein, allergic diseases include bronchial asthma, atopic dermatitis, hay fever, allergic rhinitis, food allergies, metal allergies, drug allergies, anaphylaxis, urticaria, allergic conjunctivitis, allergic bronchitis, contact dermatitis, etc.

[0014] In allergic diseases, excessive expression of BAFF in the body has been confirmed, and it has been reported that the amount of BAFF expression increases as the condition progresses. The increase in BAFF activates NIK within the cell. NIK activation promotes the intranuclear translocation of NF-κB, which enhances the differentiation of B cells, causing them to differentiate into plasma cells, and promotes antibody production from these differentiated plasma cells, thereby progressing the allergic disease.

[0015] Therefore, in order to treat patients with these diseases, it is important to suppress B cell differentiation by inhibiting BAFF-induced NIK activation and NF-κB activation, and to reduce the expression or secretion levels of BAFF. Note that, in this context, "treatment" includes not only the improvement of the symptoms but also the effect of inhibiting or delaying the progression of the symptoms.

[0016] Furthermore, in allergic diseases, NF-κB activation due to activation of NIK and the like leads to activation of B cells, Th1 cells, Th2 cells, Th17 cells, and macrophages, suppression of Treg cells, and overexpression of cytokines such as BAFF, IFNγ, IL-3, IL-4, IL-5, IL-6, IL-13, IL-17, and TNFα. Therefore, inhibiting NF-κB activation due to NIK activation and the like is important for treatment, as it suppresses the activation of B cells, Th1 cells, Th2 cells, Th17 cells, and macrophages and inhibits the expression of cytokines such as BAFF, IFNγ, IL-3, IL-4, IL-5, IL-6, IL-13, IL-17, and TNFα.

[0017] Furthermore, promoting the activation of Treg cells by inhibiting the activation of NF-κB due to NIK activation, etc. is also important in treatment. Here, treatment also includes not only the improvement of the disease condition but also the effect of suppressing or delaying the progression of the disease condition.

[0018] It has been shown that serum BAFF levels are elevated in patients with bronchial asthma compared to healthy individuals (Non-Patent Document 3). It has also been reported that elevated serum BAFF levels increase inflammatory cells in asthma model mice, and that BAFF shRNA treatment improves asthma symptoms (Non-Patent Document 4). Furthermore, it has been shown that activation of the non-classical NF-κB pathway via NIK in lymphocytes at the lesion site is involved in the pathogenesis of asthma in patients with bronchial asthma and in asthma model mice (Non-Patent Document 5).

[0019] Furthermore, in patients with bronchial asthma, activation of Th2 cells results in the secretion of cytokines such as IL-4, IL-5, IL-9, and IL-13; IL-4 converts B cell immunoglobulin from IgG to IgE; IL-5 promotes the proliferation and differentiation of eosinophils in the bone marrow, as well as their migration to tissues, activation, and survival; IL-9 promotes the proliferation of mast cells and induces inflammation; and IL-13 induces the production of nitric oxide synthase in airway epithelial cells, thereby enhancing airway hyperresponsiveness and fibrosis and inducing allergic inflammation.

[0020] It has also been shown that macrophages activate Th2 cells and the like by taking up antigens and producing leukotriene B4, chemokine ligand 2, and the like, and that they are activated by IL-4, IL-5, and the like secreted by activated Th2 cells. Furthermore, it has been reported that in patients with non-allergic bronchial asthma, asthma is caused by the activation of neutrophils by IFNγ and IL-17 secreted from Th1 cells and Th17 cells (Non-Patent Documents 6 and 7).

[0021] It has also been shown that activation of NF-κB in Th2 cells and macrophages regulates the expression of cytokines such as IL-4, IL-5, and TNFα (Non-Patent Document 8).

[0022] Furthermore, in a mouse model of bronchial asthma, BAFF shRNA was shown to reduce Th2 cells, suppress the expression of cytokines such as IL-4, and increase Treg cells, thereby improving asthma symptoms (Non-Patent Document 9).

[0023] It has also been shown that BAFF activates Th1 cells and Th17 cells, and that in T cells, BAFF activates NIK via BAFF-R, activating both the non-classical and classical NF-κB pathways (Non-Patent Documents 10 and 11).

[0024] It has been reported that serum BAFF levels are elevated in patients with atopic dermatitis compared with healthy individuals, and that this correlates with the progression of the disease and the amount of serum IgE antibodies (Non-Patent Document 12).Furthermore, in a mouse model of atopic dermatitis, treatment with NF-κB siRNA has been shown to improve symptoms and suppress the expression of inflammatory cytokines such as TNFα (Non-Patent Document 13).

[0025] Furthermore, in patients with atopic dermatitis, activation of Th2 cells leads to the secretion of cytokines such as IL-4, IL-5, IL-9, and IL-13, and IL-4 converts immunoglobulins of B cells from IgG to IgE, while IL-5 promotes the proliferation and differentiation of eosinophils in the bone marrow, their migration to tissues, activation, and survival, thereby inducing allergic inflammation. It has also been reported that patients with atopic dermatitis have an increased number of Th17 cells and increased expression of IL-17 at the lesion site (Non-Patent Document 14).

[0026] Furthermore, in a mouse model of atopic dermatitis, it has been shown that macrophages are activated and produce cytokines, which activate Th2 cells, and that macrophages are activated by IL-4, IL-5, and the like secreted by activated Th2 cells (Non-Patent Document 15). Furthermore, it has been shown that activation of NF-κB in Th2 cells and macrophages regulates the expression of cytokines such as IL-4, IL-5, and TNFα (Non-Patent Document 8).

[0027] Furthermore, in inflammatory diseases mediated by Th2 cells, such as atopic dermatitis, it has been reported that cytokines such as IL-4 and IL-13 are secreted from Th2 cells due to increased BAFF in serum, and are involved in the onset of the disease (Non-Patent Documents 16 and 17).

[0028] It has been shown that in patients with allergic diseases, sensitization to house dust such as pollen and mites increases the BAFF concentration in bronchoalveolar lavage fluid, as well as increases in lymphocyte count, neutrophil count, eosinophil count, production of inflammatory cytokines such as IL-6 and IL-13, and production of IgE and IgA antibodies, and it has been reported that increases in these cell counts, production of inflammatory cytokines, and production of IgE and IgA antibodies correlate with the BAFF concentration (Non-Patent Document 18).

[0029] Furthermore, in a pollinosis model mouse, it has been shown that the number of Th17 cells, neutrophils, and eosinophils in bronchoalveolar lavage fluid increased, and Treg cells decreased, and inflammatory cytokines such as TNFα and IL-17 increased, and NF-κB was activated (Non-Patent Document 19).

[0030] It has been shown that BAFF production levels in serum and at lesion sites are elevated in patients with allergic rhinitis compared with healthy individuals, and that this correlates with the progression and severity of the disease (Non-Patent Document 20). It has also been reported that the NF-κB pathway is activated at lesion sites in patients with allergic rhinitis, and plays an important role in the onset of the disease (Non-Patent Document 21).

[0031] Furthermore, in patients with hay fever and allergic rhinitis, dendritic cells that have taken up antigens activate Th2 cells via the activation of natural killer cells. Activated Th2 cells secrete cytokines such as IL-4 and IL-13, which induce B cells to produce IgE antibodies, leading to the development of rhinitis (Non-Patent Document 22).

[0032] Furthermore, it has been shown that in patients with hay fever and allergic rhinitis, the amount of BAFF produced correlates with the activation of Th2 cells and the expression levels of cytokines such as IL-4, IL-5, and IL-13 produced by these cells (Non-Patent Document 23). It has also been shown that BAFF activates Th17 cells, and that in T cells, BAFF activates NIK via BAFF-R, activating both the non-classical and classical NF-κB pathways (Non-Patent Documents 10 and 11).

[0033] It has been shown that BAFF concentrations in serum and intestinal lavage fluid are higher in patients with food allergies than in healthy individuals (Non-Patent Document 24).Furthermore, it has been reported that in food allergy model mice, activation of NF-κB was observed at the lesion site, and the expression of IgE antibodies and inflammatory cytokines such as IL-13, IL-25, and IL-33 was increased (Non-Patent Document 25).

[0034] In food allergies, antigen presentation from dendritic cells increases Th2 cells, and IL-4 and IL-13 expressed by these Th2 cells promote differentiation into IgE-producing B cells and enhance the migration and activation of basophils, while IL-5 and IL-9 promote the migration and activation of eosinophils (Non-Patent Document 26). Furthermore, it has been reported that BAFF production at the lesion site induces the activation and differentiation of B cells, enhances IgE production, and activates Th2 cells and eosinophils (Non-Patent Document 27).

[0035] It has been reported that serum BAFF production is elevated in animal models of anaphylaxis, and that BAFF inhibition inhibits anaphylaxis (Non-Patent Document 28). It has also been shown that activation of NF-κB is important for the expression of inflammatory cytokines and is a factor in causing anaphylaxis (Non-Patent Document 29).

[0036] In anaphylaxis, Th2 cells differentiate into IgE-producing B cells due to the expression of cytokines such as IL-4 and IL-5, and the IgE expressed by these B cells binds to high-affinity IgE receptors on the cell membranes of mast cells and basophils, promoting degranulation in the mast cells and basophils. This degranulation releases histamine, heparin, tryptase, TNFα, cytokines, and other factors, which have been shown to increase vascular permeability (Non-Patent Document 30).

[0037] Furthermore, it has been reported that BAFF production at the lesion site induces the activation and differentiation of B cells, enhanced IgE production, and activation of Th2 cells and eosinophils (Non-Patent Document 21).

[0038] It has been reported that BAFF levels in the serum of urticaria patients are higher than those of healthy individuals, and that the BAFF level correlates with the progression of the disease (Non-Patent Document 31).Furthermore, it has been shown that NF-κB is activated in lymphocytes of urticaria patients (Non-Patent Document 32).

[0039] It has been shown that in patients with urticaria, Th2 cells and Th17 cells are increased at the lesion site, and that Th17 cells are increased and Treg cells are decreased in the peripheral blood (Non-patent Documents 33 and 34).

[0040] It has also been reported that BAFF production at the lesion site induces the activation and differentiation of B cells, enhanced IgE production, and activation of Th2 cells and eosinophils (Non-Patent Document 21). Furthermore, it has been shown that BAFF activates Th1 cells and Th17 cells, and that in T cells, BAFF activates NIK via BAFF-R, activating both the non-classical and classical NF-κB pathways (Non-Patent Documents 10 and 11).

[0041] It has been shown that BAFF mRNA expression is elevated in the lesions of patients with vernal keratoconjunctivitis, a severe form of allergic conjunctivitis, compared with healthy controls, and that this expression correlates with the progression of the disease (Non-Patent Document 35).It has also been reported that NF-κB is activated in the lesions of mice with allergic conjunctivitis, resulting in increased levels of IgE antibodies and inflammatory cytokines such as IL-17 (Non-Patent Document 36).

[0042] It has also been shown that IL-4, IL-5, and IL-17 expressed by Th2 cells and Th17 cells are increased in the tears of patients with allergic conjunctivitis compared to healthy individuals, and furthermore, it has been observed that the expression of IL-4, IL-5, IL-13, and IL-17 by Th2 cells and Th17 cells is increased in mice modeling allergic conjunctivitis (Non-Patent Documents 37 and 38).

[0043] It has also been reported that BAFF production at the lesion site induces the activation and differentiation of B cells, enhanced IgE production, and activation of Th2 cells and eosinophils (Non-Patent Document 21). Furthermore, it has been shown that BAFF activates Th1 cells and Th17 cells, and that in T cells, BAFF activates NIK via BAFF-R, activating both the non-classical and classical NF-κB pathways (Non-Patent Documents 10 and 11).

[0044] In allergic bronchitis model mice, BAFF production levels in serum and at lesion sites have been shown to be increased, and this correlates with the levels of IgE antibodies and the production of inflammatory cytokines such as TNFα and IL-6 (Non-Patent Document 39). Furthermore, it has been reported that activation of NF-κB in bronchial epithelium increases lymphocyte and neutrophil counts and enhances the production of inflammatory cytokines such as IL-6, contributing to the onset of allergic bronchitis (Non-Patent Document 40). It has also been shown that allergic bronchitis model mice have increased Th2 cells and Th17 cells, and that the secretion of IL-4, IL-6, IL-13, and IL-17 increases along with an increase in specific IgE antibodies in serum (Non-Patent Document 41).

[0045] It has also been reported that BAFF production at the lesion site induces the activation and differentiation of B cells, enhanced IgE production, and activation of Th2 cells and eosinophils (Non-Patent Document 21). Furthermore, it has been shown that BAFF activates Th1 cells and Th17 cells, and that in T cells, BAFF activates NIK via BAFF-R, activating both the non-classical and classical NF-κB pathways (Non-Patent Documents 10 and 11).

[0046] It has been shown that activation of the non-classical and classical NF-κB pathways via NIK activation is important for the development of contact dermatitis (Non-Patent Document 42).In addition, in contact dermatitis model mice, increased expression of IL-4, IL-5, and IL-17 secreted by Th2 cells and Th17 cells was observed at the lesion site (Non-Patent Document 43).

[0047] It has also been reported that BAFF production at the lesion site induces the activation and differentiation of B cells, enhanced IgE production, and activation of Th2 cells and eosinophils (Non-Patent Document 21). Furthermore, it has been shown that BAFF activates Th17 cells, and that in T cells, BAFF activates NIK via BAFF-R, activating both the non-classical and classical NF-κB pathways (Non-Patent Documents 10 and 11). Enhanced IgE production has also been observed in metal allergies and drug allergies (Non-Patent Documents 44 and 45).

[0048] TNFα is secreted during inflammatory responses in inflammatory diseases. In colonic epithelial cells and mouse fibroblasts, TNFα stimulation promotes the nuclear translocation of NF-κBp52 and RelB heterodimers via activation of the non-classical NF-κB pathway, inducing inflammation. TNFα enhances the degradation of TRAF, thereby increasing the cytoplasmic amount of NIK and activating it (Non-Patent Document 46).

[0049] As described above, it can be said that it is already scientifically common knowledge that allergic diseases are caused by the overexpression of BAFF and the activation of NF-κB by NIK, etc. Therefore, pharmaceuticals and the like that can inhibit the activation of NIK and NF-κB by BAFF have a therapeutic effect on allergic diseases in which the overexpression of BAFF and the abnormal activation of NF-κB by NIK, etc. are observed.

[0050] Furthermore, studies have shown that NF-κB regulates the expression of many genes involved in inflammation, and NF-κB signaling has been found to be chronically activated in many inflammatory diseases, such as inflammatory bowel disease, sepsis, etc. Thus, compounds that can inhibit NIK and thereby attenuate the non-canonical NF-κB signaling pathway have therapeutic effects on diseases and disorders in which excessive activation of non-canonical NF-κB signaling is observed.

[0051] The following patent documents are cited regarding the inhibition of NF-κB activity. Patent Document 1 discloses an antibody that specifically binds to NF-κB-inducing kinase (NIK) / MAP3K14 or a specific portion thereof. This antibody is said to act as an immunoregulatory molecule.

[0052] Furthermore, Patent Document 2 discloses 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors useful for treating diseases such as cancer, inflammatory diseases, metabolic disorders, and autoimmune diseases.

[0053] Furthermore, Patent Document 3 discloses a substance of general formula (9) as a therapeutic agent for diseases caused by immune dysfunction.

[0054]

[0055] In the formula, R represents hydrogen or a lower alkoxy group, and A represents oxygen or a sulfonyl group. Patent Document 4 also describes that mangiferin has an anti-inflammatory effect against rheumatism and the like.

[0056] JP-A-2007-537708 JP-A-2016-531858 JP-A-57-16821 JP-A-2009-023935

[0057] Thu M,iichmond A::ytokine Growttヲooto 200100, 211,2133-226. O,Orr A,Pieri K,aaleur DW,ーeng P,oppt ,Charterss M,ァenttz ,Parmelee、、 1,1alperina O,1iri 4,oschkee Vョardelli「「Caarrelll,ウoウyreenfield W,2uben MM,Oleen ィ3rkeee 4,2ilbert4M:ciencee.19 99,2855,2600-263. W,ュubarak AMir ウ。ii M,Mickymaaay yyyykummar b,。lsaaa SAAlmalkii SG,Alghofaili F,lleemaa AK,,lanagan BP:audii Bioll 3ci.20021,28,7455-7459 4.445. ::ife ウcii. 2020, 24111,1171172.2000 L,Jahani Pウvoward E,eelou ,,「aaieee 2,3oroosh P,。kbari O:Celll 2019, 200, 450,090-4524, 15,500,000,000,000,000 MT:Ynt Mol 3ci.200211,22,44428.2. 4,6illasenor A,Izquirrdo MBBarkermTejeda 43,2adzikowska U,3okolowska M,「arber D:oront 200211,122,6920044. M!Bagam P,ウahoo MKッsorio ,Batraa S:Arch Immunol Ther ・xp.20116,644,46304483. Mィ,licksteinn J,Cai Q,Cai C,Zhouu ,) U,ォim !W,Kim P:iu W,Kanangaat 3,oo 44:3lin 9mmunol.2011,138,222-2300. GABerstad A:cand J Immunoll.20111,73,11-7.1arrdaam ウmmrikk 2014,44,509,414,44,509,400,000,000,000 KW,(ong / YY4ohn M(:iim KE::iin xp The 4,2amasakii 4,・ndo 4,4amano K,ウogabb K,3eta Y,ッhgi 4,ッkada (::ntt 4 2015, 489, 2611-2677. LJ,Yesner AL,,rrasssl N,Ro A6,Ropner S,Kraef C,Leclairreclaaeee、 P,Messerer DAMohrmann L,Nikke eee,o ,Soll DWoopen 3M:lin 2017, 174,733-83.61121121 (Pッde Carvalho GC,)ietrrobon AAaro AC,Ramos 。,,ereira NV,Orfalii ,oooo V,da Silva LPヲ,otto Mョ、os Reis MMセoo MNo:xp Dermatol,2021,doi: 10.1111111111111144442.7111144442. N,Gilmann-aachs A,Kwak-Kim m::rrooo Immunol.20020,111,20025.5. JAoki N,ゥwamoto ウoishiuraa H,Chibbaa 4,Watanabe N::n 200100, 78, 108-114.4.5. 2,Chusttz T,Liu MC4cchleimer ,l::a Allergy Clin 2009, 123, 369-375.35. L,コhou ,Yang L,,uo S::nt Archh Alleyy Immunoll.20020,1811,3442-3542.5.5. 8,(an M,ﺈhou L,i JWang JLii ,Luo oo) 2.: 9nt 4 Pediatr Otorhinolaryngoll.2014,78,21566-201556 SZ,Ma FM,Zhao44.:・ur Arch 2011 3,270,13229-1334. 2018, 9,2816, 100,000,000. W,ﷷang !,Chenn ,Sun C,コhou L,ャii、 ::Eur 4 Pediatrrrr014,1733,10333000000000 G。,illestol K,Valeur 4,Berstad . 4.20100,302,664-73.100000000000032266073.15 3.:3iochem Pharmacoll.20222,195,1144867.3. A,Hershkop ​​AM,Ponce M,Eiwegger r?Aroop Immunol 4her ・xp.2018,66,161-1770. 7,ャi M,コhegg b4,コhan oZheng hbiib be) 8.:9nt Immunopharmacol. ,104,1008415. P。,Nayak 3,Rerzog WMoreel,「yrreee 34.:31in Immunol.2015,158,140-147. L,Klei BB,rotta M,Goughh P,ーolley KPBertin J,ウumpter Zumpt PC,Mc。llisterrrucas LM::4 Immmuuo 20200, 2004, 2337-2348.80120012001 CP,Raque A,Pattanaik D,usiin 4, , r sshnaswamy y::ot t ュol The K,Vadasz Z,Perii ,Halazs K,Toubbii・mmm 2012, 73, 620-6220. ABishara ,。mital ABambergerrrSabo E,Grushko G,Toubi E.:Clin Exp Allergy.2005,35,221-225.Moy AP,Murali M,Nazarian RM.:IJ Cutan Pathol.2016,43,372-378.Yu Q,Lin W,Zhang J,Peng L,Kong Q,Zhong R,Lan Y,Xiao M,Chen M.Medicine. 2020,99,e22014.Yoshida K,Shoji J,Ishimori A,Nakashima M,Inada N,Sawa M.:Nippon Ganka Gakkai Zasshi.2014,118,368-377.Bai MT,Li Y,Hu ZL.:Int J Ophthalmol.2021,14,955-964.Yan A,Luo G,Zhou Z,Hang W,Qin D.:Allergol Immunopathol.2018,46,144-148.Chen X,Deng R,Chi W,Hua X,Lu F,Bian F,Gao N,Li Z,Pflugfelder SC,de Paiva CS,Li DQ.:Allergy.2019,74,910-921.Liang ZQ,Tu PC,Ji JJ,Xing QQ,Zhao X.:Biomed Pharmacother.2020,132,110801.Pantano C,Ather JL,Alcorn JF,Poynter ME,Brown AL,Guala AS,Beuschel SL,Allen GB,Whittaker LA,Bevelander M,Irvin CG,Janssen-Heininger YM.:Am J Respir Crit Care Med.2008,177,959-969.Cheng FL,An YF,Xue JM,Wang YJ,Ding XW,Zhang YT,Zhao CQ.:Int Forum Allergy Rhinol.2021,doi: 10.1002 / alr.22914.Piao W,Xiong Y,Famulski K,Brinkman CC,Li L,Toney N,Wagner C,Saxena V,Simon T,Bromberg JS. : Nat Commun. 2018, 9, 3020. Piao CH, Fan YJ, Nguyen TV, Song CH, Jeong HJ, Chai OH. :J Dermatolog Treat. 2020, 1-8. Katherine A, Aleksandr B, Jenny R. :J Immunotoxicology. 2019, 16, 1, 87-124. Brian A. : Antibodies. 2014, 3, 56-91. Bhattacharyya S, Dudeja PK, Tobacman JK. :J Biol Chem. 2010, 285, 39511-39522. Hu L, Wu W, Chai X, Luo J, Wu Q. :Bioorg Med Chem Lett. 2011, 21, 4013-4015. ,

[0058] As shown in the patent documents, antibody preparations are mainly used as drugs that suppress cytokines expressed by immune cells, but with the exception of mangiferin in Patent Document 4, the route of administration is intravenous, which places a heavy burden on patients. Therefore, the object is to provide a therapeutic drug and an ameliorating composition that inhibits NIK by oral administration and improves allergic diseases.

[0059] Furthermore, although the mangiferin of Patent Document 4 is effective when administered orally, the required intake amount is large and it is not easy to take even when administered orally. Therefore, there has been a demand for more effective or active therapeutic agents and improving compositions.

[0060] Furthermore, new or improved forms of existing drugs that inhibit kinases such as NIK are constantly needed to develop effective pharmaceuticals, such as those used to treat allergic diseases.

[0061] In order to solve the above problems, the present inventors searched for compounds that inhibit NIK and found that certain substances having a xanthone skeleton have NIK inhibitory activity. They confirmed that these substances completely cured mice with allergic rhinitis, such as bronchial asthma, atopic dermatitis, and hay fever. Furthermore, they confirmed that this substance suppresses the activation of NIK, NF-κBp52, and NF-κBp65 induced by BAFF, and inhibits the differentiation of B cells into plasmablasts and plasma cells induced by BAFF. They also confirmed that this substance induces dedifferentiation of plasma cells into immature B cells, leading to the completion of the present invention.

[0062] That is, the pharmaceutical composition for improving allergic diseases according to the present invention is characterized by containing at least one compound selected from the following: mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin.

[0063] The pharmaceutical composition for ameliorating allergic diseases according to the present invention can ameliorate allergic diseases, and can dramatically cure the symptoms of, for example, bronchial asthma, atopic dermatitis, and allergic rhinitis such as hay fever. Furthermore, it is effective when administered orally, and when administered to humans, it places a very small burden on patients.

[0064] Furthermore, allergic diseases are thought to develop through the activation of B cells and T cells and the production of antibodies such as IgE due to the overexpression of BAFF and activation of the NF-κB pathway. That is, allergic diseases develop because of the same cause, and it is thought that many allergic diseases other than the allergic diseases listed above also have the same cause. Therefore, the pharmaceutical composition for ameliorating allergic diseases according to the present invention, which inhibits NIK activity, is thought to have an effect of improving not only bronchial asthma, atopic dermatitis, and allergic rhinitis such as hay fever shown in the examples, but also all allergic diseases accompanied by overexpression of BAFF and activation of the NF-κB pathway.

[0065] 1 is a graph showing the change in ear swelling over time when MC903 was applied to the ears of mice, and mice were allowed to develop atopic dermatitis, and then norathyriol, betamethasone ointment, and delgocitinib ointment were applied to the mice. Photographs are shown showing the condition of the ear skin of the mice on day 7 after the onset of atopic dermatitis in FIG. 1. (a) shows the results for control, (b) for vehicle (MC903 application), (c) for norathyriol, (d) for MC903 + betamethasone ointment, and (e) for MC903 + delgocitinib ointment. This graph shows the results of measuring IgE antibodies in serum collected from mice after 7 days in FIG. 1. This graph shows the results of measuring TSLP secretion in the tissue collected from mouse ear tissue after 7 days in FIG. 1. This graph shows the results of measuring IL-4 secretion in the tissue collected from mouse ear tissue after 7 days in FIG. 1. 1 is a graph showing the measurement of IL-5 secretion in mouse ear tissue collected 7 days after the administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and allowed to develop allergic rhinitis. FIG. 1 is a graph showing the measurement of the number of nasal scratching behaviors when norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine were administered to mice immunized with ovalbumin and allowed to develop allergic rhinitis. FIG. 1 is a graph showing the measurement of OVA-IgE antibody in mouse serum collected after administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and allowed to develop allergic rhinitis. 1 is a graph showing the measurement of IgE antibody after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developed allergic rhinitis, and the measurement of IgE antibody after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developed allergic rhinitis, and the measurement of BAFF secretion in the serum after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice.1 is a graph showing the measurement of serum IL-4 secretion in mice immunized with ovalbumin and allowed to develop allergic rhinitis, after which norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine were administered to the mice. 2 is a graph showing the measurement of serum IL-5 secretion in mice immunized with ovalbumin and allowed to develop allergic rhinitis, after which norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine were administered to the mice. 3 is a graph showing the measurement of serum IL-17 secretion in mice immunized with ovalbumin and allowed to develop allergic rhinitis, after which norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine were administered to the mice. 1 is a graph showing the measurement of the number of coughs when mice immunized with ovalbumin and allowed to develop bronchial asthma were administered norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine. 2 is a graph showing the measurement of OVA-IgE antibodies after collecting mouse serum and administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and allowed to develop bronchial asthma. 3 is a graph showing the measurement of IgE antibodies after collecting mouse serum and administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and allowed to develop bronchial asthma. 1 is a graph showing the measurement of BAFF secretion in serum obtained by administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and caused to develop bronchial asthma, followed by collection of mouse serum. 2 is a graph showing the measurement of IL-4 secretion in serum obtained by administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and caused to develop bronchial asthma, followed by collection of mouse serum. 3 is a graph showing the measurement of IL-5 secretion in serum obtained by administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and caused to develop bronchial asthma, followed by collection of mouse serum.1 is a graph showing the measurement of serum IL-17 secretion after administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developed bronchial asthma, followed by collection of mouse serum. 2 is a graph showing the measurement of diarrhea frequency after administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developed food allergy. 3 is a graph showing the measurement of OVA-IgE antibody after administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developed food allergy. 1 is a graph showing the results of measuring IgE antibodies after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developing food allergy, and then collecting mouse serum. 2 is a graph showing the results of measuring BAFF secretion after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developing food allergy, and then collecting mouse serum. 3 is a graph showing the results of measuring IL-4 secretion after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developing food allergy, and then collecting mouse serum. 1 is a graph showing the measurement of IL-5 secretion in serum after administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developed food allergy, followed by collection of mouse serum. 2 is a graph showing the measurement of IL-17 secretion in serum after administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with ovalbumin and developed food allergy. 3 is a graph showing the measurement of the number of nose-scratching behaviors in mice immunized with cedar pollen and developed hay fever after administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine.1 is a graph showing the measurement of the number of sneezes when mice immunized with cedar pollen and allowed to develop hay fever were administered norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine. 2 is a graph showing the measurement of IgE antibodies after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with cedar pollen and allowed to develop hay fever. 3 is a graph showing the measurement of IL-4 secretion in the serum after administering norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine to mice immunized with cedar pollen and allowed to develop hay fever. 1 shows graphs of measurements of serum IL-5 secretion in mice immunized with cedar pollen and developed hay fever, followed by administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine. 1 shows graphs of measurements of serum IL-17 secretion in mice immunized with cedar pollen and developed hay fever, followed by administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine. 1 shows graphs of measurements of serum IL-17 secretion in mice immunized with cedar pollen and developed hay fever, followed by administration of norathyriol, mangiferin 8a, tofacitinib, dexamethasone, and olopatadine. 1 shows a panel of measurements of IgM and IgD expression in cells stimulated with BAFF after addition of a reagent (compound) to mouse B cells. 1 shows the results for the control, (b) for BAFF only, and (c) for BAFF and mangiferin. 1 shows a panel of measurements of IgM and IgD expression in cells stimulated with BAFF after addition of a reagent (compound) to mouse B cells. (d) shows the results for BAFF and mangiferin 8a, (e) for BAFF and norathyriol, and (f) for BAFF and 1,3,5,6-tetrahydroxyxanthone. This panel shows the results of adding a reagent (compound) to mouse B cells, followed by BAFF stimulation, to measure IgM and IgD expression in the cells using flow cytometry. (g) shows the results for BAFF and xanthohydrol, (h) for BAFF and α-mangostin, and (i) for BAFF and γ-mangostin. This panel shows the results of adding a reagent (compound) to mouse B cells, followed by BAFF stimulation, to measure CD138 expression in the cells using flow cytometry.(a) shows the results for mangiferin, (b) for mangiferin 8a, and (c) for norathyriol. This panel shows the results of adding a reagent (compound) to mouse B cells, followed by BAFF stimulation, to measure CD138 expression in the cells using flow cytometry. (d) shows the results for 1,3,5,6-tetrahydroxyxanthone, and (e) shows the results for xanthohydrol. This panel shows the results of adding a reagent (compound) to mouse B cells, followed by BAFF stimulation, to measure CD138 expression in the cells using flow cytometry. (f) shows the results for α-mangostin, and (g) shows the results for γ-mangostin. 1 is a photograph showing the results of Western blotting analysis of the expression of phospho-NIK, NIK, NF-κB p52 nuclear, NF-κB p65 nuclear, and Lamin when mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin were added to pre-B cells collected from mice and then stimulated with BAFF. 2 is a graph showing the measurement of TNFα in the culture supernatant of cells collected from mice and then stimulated with BAFF after adding a reagent (compound). 3 is a graph showing the measurement of IL-6 in the culture supernatant of cells collected from mice and then stimulated with BAFF after adding a reagent (compound). 1 shows a panel of experiments in which IFNγ expression in T cells collected from inflammatory model mice administered with a reagent (compound) was measured using flow cytometry. (a) shows the results for mangiferin 8a, and (b) shows the results for norathyriol. 2 shows a panel of experiments in which IL-4 expression in T cells collected from inflammatory model mice administered with a reagent (compound) was measured using flow cytometry. (a) shows the results for mangiferin 8a, and (b) shows the results for norathyriol. 3 shows a panel of experiments in which IL-17A expression in T cells collected from inflammatory model mice administered with a reagent (compound) was measured using flow cytometry. (a) shows the results for mangiferin 8a, and (b) shows the results for norathyriol. 4 shows a panel of experiments in which Foxp3 expression in T cells collected from inflammatory model mice administered with a reagent (compound) was measured using flow cytometry. (a) shows the results for mangiferin 8a, and (b) shows the results for norathyriol.1 is a graph examining the effect of each compound on the cell proliferation ability of mouse B cells stimulated with LPS. This graph is a graph examining the effect of each compound on the cell proliferation ability of mouse macrophages stimulated with LPS. This panel shows mouse B cells treated with a reagent (compound) and then stimulated with LPS, where the IgM and IgD expression in the cells was measured using flow cytometry. (a) shows the control, and (b) shows the results for LPS only. This panel shows mouse B cells treated with a reagent (compound) and then stimulated with LPS, where the IgM and IgD expression in the cells was measured using flow cytometry. (c) shows the results for LPS and mangiferin 8a, and (d) shows the results for LPS and norathyriol. This panel shows mouse B cells treated with a reagent (compound) and then stimulated with LPS, where the CD138 expression in the cells was measured using flow cytometry. (a) shows the results for mangiferin 8a, and (b) shows the results for norathyriol. This panel shows the results of adding each reagent (compound) to mouse macrophages and then stimulating them with LPS, where CD11b and F4 / 80 expression was measured using flow cytometry. (a) shows the control, and (b) shows the results for LPS only. This panel shows the results of adding each reagent (compound) to mouse macrophages and then stimulating them with LPS, where CD11b and F4 / 80 expression was measured using flow cytometry. (c) shows the results for mangiferin 8a and LPS, and (d) shows the results for LPS and norathyriol. This panel shows the results of adding each reagent (compound) to mouse macrophages and then stimulating them with LPS, where CD80 expression was measured using flow cytometry. (a) shows the results for mangiferin 8a, and (b) shows the results for norathyriol. 1 is a photograph showing the results of Western blotting analysis of the expression of phospho-NIK, NIK, NF-κB p52 nuclear, NF-κB p65 nuclear, and Lamin when mangiferin 8a and norathyriol were added to pre-B cells collected from mice and then stimulated with LPS. 2 is a graph showing the results of examining the inhibitory effect of each compound on the secretion of TNFα when mouse B cells were stimulated with LPS.1 is a graph showing the results of examining the effect of each compound on the amount of IL-6 secreted when mouse B cells are stimulated with LPS. 2 is a graph showing the results of examining the effect of each compound on the amount of TNFα secreted when mouse macrophages are stimulated with LPS. 3 is a graph showing the results of examining the effect of each compound on the amount of IL-6 secreted when mouse macrophages are stimulated with LPS.

[0066] The pharmaceutical compositions for improving allergic diseases according to the present invention will be described below. These products are pharmaceutical compositions and NIK inhibitors. The following description is an example of one embodiment and one example of the present invention, and the present invention is not limited to the following description. The following embodiment can be modified as long as it does not deviate from the spirit of the present invention.

[0067] Furthermore, in this specification, "improvement" may include not only treating the target disease or symptom but also reducing or suppressing the symptom. Furthermore, "treatment" includes not only recovery from the disease state but also the effect of suppressing or delaying the progression of the disease state.

[0068] The pharmaceutical composition for improving allergic diseases according to the present invention contains at least one compound selected from mangiferin (formula (3)), mangiferin 8a (formula (1)), norathyriol (formula (2)), and 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)) as an active ingredient. Formula (1) is 1,2',3',4',6-penta-O-propionylmangiferin, hereinafter referred to as "mangiferin 8a." Mangiferin is shown in formula (3). Formula (2) is 1,3,6,7-tetrahydroxyxanthone, hereinafter referred to as "norathyriol."

[0069]

[0070]

[0071]

[0072] As can be seen from formula (1), mangiferin 8a is a compound in which a propionyl group is ether-bonded to a part of the hydroxyl group of mangiferin (see formula (3)). As shown in the following examples, this compound exhibits superior NIK activity inhibition to mangiferin and exhibits a high preventive effect against allergic diseases.

[0073] Norathyriol (CAS number: 3542-72-1) is a compound in which a hydroxy group has been added to a portion of xanthone (CAS number: 90-47-1), and has a xanthone skeleton similar to mangiferin 8a. Similarly to mangiferin 8a, norathyriol exhibits a stronger NIK activity inhibition than mangiferin and a higher preventive effect against allergic diseases. In addition, 1,3,5,6-tetrahydroxyxanthone (CAS number: 5084-31-1: formula (4)), xanthohydrol (CAS number: 90-46-0: formula (5)), α-mangostin (CAS number: 6147-11-1: formula (6)), and γ-mangostin (CAS number: 31271-07-5: formula (7)) are also compounds having a xanthone skeleton, and like norathyriol and mangiferin 8a, they exhibit greater inhibition of NIK activity than mangiferin and exhibit high preventive effects against allergic diseases.

[0074]

[0075]

[0076]

[0077]

[0078] These compounds, like mangiferin, are low molecular weight compounds, are highly soluble in water, and can be taken orally. The pharmaceutical composition for improving allergic diseases according to the present invention contains at least one of the above compounds as an active ingredient. It may also contain other pharmaceutically acceptable ingredients. Furthermore, the pharmaceutical composition for improving allergic diseases according to the present invention may contain a plurality of these compounds.

[0079] The pharmaceutical composition for improving allergic diseases according to the present invention can be provided as a therapeutic agent for allergic diseases (which may also be referred to as a pharmaceutical composition). The compound of the present invention can also be provided as a NIK inhibitor. As a pharmaceutical composition, the composition of the present invention can be effective not only by intravenous, subcutaneous, or intramuscular injection, but also by oral administration. Therefore, it can be provided as an internal preparation. For example, a powdered pharmaceutical composition for improving allergic diseases can be formulated and provided as capsules, granules, powders, tablets, etc. When preparing oral preparations, additives such as binders, lubricants, disintegrants, colorants, flavoring agents, preservatives, antioxidants, and stabilizers can be added, and capsules, granules, powders, and tablets can be produced by conventional methods.

[0080] Furthermore, the pharmaceutical composition for improving allergic diseases according to the present invention may be formulated into topical preparations such as liquids, ointments, creams, gelling agents, patches, and aerosols, and administered parenterally. When used as topical preparations, water, lower alcohols, solubilizers, surfactants, emulsion stabilizers, gelling agents, adhesives, and other necessary base components may be blended. Furthermore, additives such as vasodilators, adrenocortical hormones, keratolytic agents, moisturizers, disinfectants, antioxidants, refreshing agents, fragrances, and colorings may be appropriately blended.

[0081] Furthermore, the pharmaceutical composition for ameliorating allergic diseases according to the present invention can also be provided as a processed food, meaning that even when ingested as a processed food, the pharmaceutical composition for ameliorating allergic diseases according to the present invention can achieve the same effects as the pharmaceutical composition for ameliorating allergic diseases according to the present invention.

[0082] Processed foods include not only general processed foods, including luxury foods and health foods such as candy, gum, jelly, biscuits, cookies, rice crackers, bread, noodles, fish and meat paste products, tea, soft drinks, coffee drinks, milk drinks, whey drinks, lactic acid bacteria drinks, yogurt, ice cream, and pudding, but also health-promoting foods such as foods for specified health uses and foods with nutrient functions specified in the Ministry of Health, Labor and Welfare's Health Function Food System, and further include nutritional supplements, feed, food additives, etc.

[0083] The processed foods of the present invention can be prepared by adding a pharmaceutical composition for improving allergic diseases to the ingredients of these processed foods. The addition of mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, or γ-mangostin to these processed foods is excluded from application if ingredients containing these substances are used as ingredients. However, processed foods containing these substances in amounts exceeding the amount contained in the ingredients are considered to be processed foods of the present invention. The pharmaceutical composition for improving allergic diseases of the present invention will be described below with reference to examples.

[0084] The diseases targeted by the pharmaceutical composition for ameliorating allergic diseases according to the present invention are, to reiterate, bronchial asthma, atopic dermatitis, hay fever, allergic rhinitis, food allergy, metal allergy, drug allergy, anaphylaxis, urticaria, allergic conjunctivitis, allergic bronchitis, and contact dermatitis.

[0085] In addition, diseases other than those mentioned above can also be targeted if they are judged to be allergic diseases due to overexpression of BAFF or activation of the NF-κB pathway.

[0086] <Synthesis of Mangiferin 8a> Mangiferin 8a was obtained in two steps by synthesizing the starting material 1,3,2',3',4',6,6',7-octa-O-propionylmangiferin and then further synthesizing it based on that.

[0087] (1) Synthesis of 1,3,2',3',4',6,6',7-octa-O-propionylmangiferin Mangiferin (2.1 g, 4.98 mmol), propionic anhydride (12.8 mL, 99.4 mmol), and dry pyridine (60 mL) were heated at 80°C for 5 hours. The reaction mixture was poured into ice water (400 mL) and extracted with ethyl acetate. The ethyl acetate layer was washed successively with ice-cold 10% sulfuric acid, saturated aqueous sodium bicarbonate, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified using column chromatography (n-hexane / ethyl acetate = 1 / 1) to obtain 1,3,2',3',4',6,6',7-octa-O-propionylmangiferin (3.71 g, 86%) of formula (8) as a colorless solid.

[0088]

[0089] The NMR spectrum is shown below: IR (KBr): 1774, 1755, 1667, 1620, 1458, 1354, 1273, 1157, 1114, 1083 cm -1 . 1 H NMR (800 MHz, DMSO-d 6 , 25 °C) δ: 0.71-0.77 / 0.93-0.97 (each 3H, m, COCH 2 CH 3 ), 0.98-1.02 / 1.12-1.16 / 1.19-1.28 (each 6H, m, COCH 2 CH 3 ), 1.92-2.01 (2H, m, COCH 2 CH 3 ), 2.17-2.32 (6H, m, COCH 2 CH 3 ), 2.60-2.94 (8H, m, COCH 2 CH 3), 3.86-3.92 (1H, m, H-6’a), 4.21-4.30 (2H, m, H-5’ and H-6’b), 5.01-5.06 (1H, m, H-4’), 5.10-5.20 (1H, m, H-1’), 5.45-5.53 (2H, m, H-2’ and H-3’), 7.51 / 7.53 (1H, each s, H-4), 7.68 / 7.69 (1H, each s, H-5), 7.97 / 7.98 (1H, each s, H-8). 13 C NMR (200 MHz, DMSO-d 6 25 ℃) δ: 8.64 / 8.75 / 8.77 / 8.91 / 8.94 / 8.96 / 9.00 / 9.13 / 9.16 (COCH 2 CH 3 ), 26.58 / 26.63 / 26.7 / 26.8 / 26.89 / 26.94 / 27.0 / 27.1 / 27.32 / 27.34 (COCH 2 CH 3 ), 62.1 / 62.2 (C6’), 68.18 / 68.20 (C4’), 69.6 / 70.0 (C2’), 70.8 / 71.3 (C1’), 73.5 / 73.6 (C3’), 75.0 / 75.1 (C5’), 110.2 / 111.8 (C4), 111.6 / 112.7 (C9a), 113.2 / 113.3 (C5), 118.8 / 118.9 (C2), 119.6 / 119.7 (C8a), 120.3 / 120.4 (C8), 139.5 / 139.6 (C7), 147.9 (C6), 149.1 / 150.9 (C1), 152.47 / 152.51 (C8b), 153.4 / 154.8 (C4a), 156.5 / 156.8 (C3), 170.9 / 171.04 / 171.06 / 171.09 / 171.67 / 171.72 / 171.9 / 172.4 / 172.6 / 172.7 / 173.18 / 173.22 / 173.51 / 173.54 (COCH 2 CH 3 ), 173.1 (C9). HRMS (ESI) m / z: [M+Na] + Calcd for C 43 H 50O 19 Na 893.2839; Found 893.2853. That was it.

[0090] (2) Synthesis of mangiferin 8a (1,2',3',4',6-penta-O-propionylmangiferin) A mixed solution of 1,3,2',3',4',6,6',7-octa-O-propionylmangiferin (3.7 g, 4.25 mmol), ammonium acetate (3.8 g, 49.4 mmol), methanol (80 mL) and water (40 mL) was stirred at room temperature for 5.5 hours. After distilling off methanol from the reaction solution by concentration under reduced pressure, the residue was diluted with ethyl acetate (100 mL). The mixture was washed with water and saturated brine successively, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography [CHCl 3 / CH 3 The pale yellow solid (2.54 g) obtained by purification using HCl (20:1)] was dissolved in methanol (80 mL) and decolorized with activated carbon to obtain mangiferin 8a (2.16 g, 73%) of formula (1) as a colorless solid.

[0091] The NMR spectrum is shown below: IR (KBr): 3406, 1751, 1620, 1462, 1354, 1284, 1192, 1083 cm -1 . 1 H NMR (800 MHz, DMSO-d 6 , 25 °C) δ: 0.74 / 0.94 (each 3H, t-like, J = 7.6, COCH 2 CH 3 ), 0.97-1.02 (6H, m, COCH 2 CH 3 ), 1.20 / 1.23 (each 1.5H, t-like, J = 7.6, COCH 2 CH 3 ), 1.92-2.02 (2H, m, COCH 2 CH 3 ), 2.15-2.33 (6H, m, COCH 2 CH 3 ), 2.61-2.86 (2H, m, COCH 2 CH3 ), 3.85 (0.5H, dd-like, J = ca. 12.5, 1.9, H-6a’), 4.05 (0.5H, br d-like, J = ca. 12.5, H-6a’), 4.07 (0.5H, ddd, J = 9.8, 4.7, 1.9, H-5’), 4.09-4.14 (0.5H, m, H-6b’), 4.11 (0.5H, br d-like, J = ca. 9.5, H-5’), 424 (0.5H, dd, J = 12.5, 4.7, H-6b’), 4.96 (0.5H, d, J = 9.9, H-1’), 5.00 (0.5H, dd, J = 9.5, 9.5, H-4’), 5.02 (0.5H, dd, J = 9.8, 9.8, H-4’), 5.16 (0.5H, d, J = 10.0, H-1’), 5.35 (0.5H, dd, J = 9.5, 9.5, H-3’), 5.40 (0.5H, dd, J = 9.8, 9.5, H-3’), 5.49 (0.5H, dd, J = 10.0, 9.5, H-2’), 5.84 (0.5H, dd, J = 9.9, 9.5, H-2’), 6.72 / 6.75 (each 0.5H, s, H-4), 6.80 / 6.81 (each 0.5H, s, H-5), 7.29 / 7.30 (each 0.5H, s, H-8), 9.62 / 10.5 (each 1H, br s, OH), 11.2 / 11.4 (each 0.5H, br s, OH). 13 C NMR (200 MHz, DMSO-d 6 , 25 ℃) δ: 8.81 / 8.86 / 8.96 / 9.02 / 9.06 / 9.11 / 9.12 / 9.20 (COCH 2 CH 3 ), 26.6 / 26.89 / 26.91 / 26.94 / 27.00 / 27.04 / 27.1 / 27.4 (COCH 2 CH 3), 62.1 / 62.3 (C-6'), 68.2 / 68.3 (C-4'), 68.7 / 70.4 (C-2'), 71.0 / 71.1 (C-1'), 73.8 / 74.1 (C-3'), 74.6 / 75.2 (C-5'), 99.5 / 100.8 (C-4), 102.5 (C-5), 106.6 / 107.8 (C-9a), 109.1 (C-8), 113.3 (C-2), 114.0 / 114.1 (C-8a), 143.8 (C-7), 149.77 / 149.82 (C-6, C-1), 151.3 (C-1), 153.3 (C-8b), 157.5 / 157.7 (C-4a), 160.7 / 162.2 (C-3), 171.1 / 171.9 / 172.2 / 172.5 / 172.8 / 173.1 / 173.4 / 173.6 (COCH 2 CH 3 ) 172.68 / 172.71 (C-9). HRMS (ESI) m / z: [MH] - Calcd for C 34 H 37 O 16 701.2076; Found 701.2070. That was all.

[0092] <Synthesis of Norathyriol> Norathyriol was synthesized according to the method of Non-Patent Document 47.

[0093] The synthesis method shown in this example can be briefly explained as follows. Specifically, according to the method described in the literature (Non-Patent Document 47), 2,4,5-trimethoxybenzoic acid (Compound II) was treated with thionyl chloride to obtain 2,4,5-trimethoxybenzoyl chloride (Compound III). Next, the obtained compound (Compound III) was subjected to a Friedel-Crafts reaction with 1,3,5-trimethoxybenzene (Compound IV) to obtain 2-hydroxy-2',4,4',5,6'-pentamethoxybenzophenone (Compound V). Furthermore, this compound (V) was treated with tetrabutylammonium hydroxide to obtain 1,3,6,7-tetramethoxyxanthone (Compound VI). Subsequently, demethylation was carried out to obtain norathyriol (Compound I) in a 39% yield.

[0094] The synthetic route of this example is described in detail below.

[0095] (1) Method for producing 2,4,5-trimethoxybenzoic acid chloride (Compound III) Thionyl chloride (5 mL) was gradually added to 2,4,5-trimethoxybenzoic acid (Compound II, 8.49 g, 0.040 mol) at room temperature under an argon atmosphere to dissolve the acid, and the mixture was heated under reflux for 6 hours. After completion of the reaction, the reaction mixture was evaporated under reduced pressure to obtain 2,4,5-trimethoxybenzoic acid chloride (Compound III, 8.30 g, 90%). The obtained Compound (III) was immediately used in the next reaction.

[0096] (2) Method for producing 2-hydroxy-2',4,4',5,6'-pentamethoxybenzophenone (Compound V) Aluminum chloride (16 g) was gradually added to a mixed suspension of 2,4,5-trimethoxybenzoyl chloride (Compound III, 8.07 g, 0.035 mol) obtained as described above, 1,3,5-trimethoxybenzene (Compound IV, 6.48 g, 0.0385 mol), and anhydrous diethyl ether (500 mL) at room temperature under an argon atmosphere, and the reaction mixture was then stirred at room temperature for 48 hours. The solvent was evaporated from the reaction mixture under reduced pressure, and water was added to the residue, followed by extraction with ethyl acetate. The extract was washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was removed by filtration using pleated filter paper, and the solvent was evaporated from the filtrate under reduced pressure to obtain a crude product. The resulting crude product was purified by silica gel column chromatography (n-hexane:ethyl acetate=1:1, v / v) to obtain 2-hydroxy-2′,4,4′,5,6′-pentamethoxybenzophenone (Compound V, 8.43 g, 69%).

[0097] (3) Method for Producing 1,3,6,7-Tetramethoxyxanthone (Compound VI) 2-Hydroxy-2',4,4',5,6'-pentamethoxybenzophenone (Compound V, 6.97 g, 0.020 mol) obtained as described above was dissolved in a mixed solvent of pyridine (10 mL) and water (10 mL), and 40% aqueous tetrabutylammonium hydroxide solution (5 mL) was added. The mixture was heated under reflux for 6 hours. The resulting reaction mixture was poured into 5% hydrochloric acid and then extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and the desiccant was filtered off using pleated filter paper. The filtrate was then distilled under reduced pressure to obtain a crude product. The resulting crude product was purified by silica gel column chromatography (n-hexane:ethyl acetate=1:1, v / v) to obtain 1,3,6,7-tetramethoxyxanthone (Compound VI, 5.82 g, 92%).

[0098] (4) Method for Producing Norathyriol (Compound I) A mixture of 1,3,6,7-tetramethoxyxanthone (Compound VI, 4.74 g, 0.015 mol) obtained as described above and pyridine hydrochloride (5.00 g) was heated and stirred at 200°C for 6 hours. The resulting reaction mixture was allowed to cool to room temperature, poured into 5% hydrochloric acid, and then extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and the desiccant was filtered off using pleated filter paper. The filtrate was then distilled under reduced pressure to remove the solvent, yielding a crude product. The resulting crude product was purified by silica gel column chromatography (chloroform:methanol = 7:1, v / v) to yield norathyriol (Compound I, 2.65 g, 68%) of formula (2).

[0099] The results of examining the allergic disease-inhibiting effect of the compound according to the present invention are shown below. Example 1: Test for the anti-inflammatory effect of a compound having a xanthone skeleton on atopic dermatitis. 2 nM MC903 was applied to the right auricle of a 6-week-old male Balb / c (Shimizu Experimental Materials). Starting 8 hours later, 5% norathyriol solution (containing 0.05 mg of norathyriol in 1 mL of ethanol), betamethasone ointment, and delgocitinib ointment were applied to the auricle for 7 days. Swelling of the auricle skin was measured using a vernier caliper. The day on which the compound was first applied was designated day 0. Betamethasone and delgocitinib are currently used clinically for atopic dermatitis and were used as control drugs in this example.

[0100] Those to which neither MC903 nor norathyriol was applied are called the control group, those to which MC903 was applied are called the vehicle group, those to which 5% norathyriol solution was applied are called the 5% norathyriol application group, those to which betamethasone ointment was applied are called the betamethasone application group, and those to which delgocitinib ointment was applied are called the delgocitinib application group.

[0101] FIG. 1 shows the results of ear swelling. Referring to FIG. 1, the horizontal axis indicates the number of days elapsed, and the vertical axis indicates swelling of the ear skin. Solid white circles indicate the control group (labeled "control"). Solid black squares indicate the vehicle group (labeled "vehicle"), dotted black diamonds indicate the 5% norathyriol solution application group (labeled "MC903 + 5% norathyriol"), dashed black crosses indicate the betamethasone application group (labeled "MC903 + betamethasone ointment"), and dashed black triangles indicate the delgocitinib application group (labeled "MC903 + delgocitinib ointment"). In addition, "*" indicates significant differences (P<0.01) compared to the control group.

[0102] In the vehicle group (black square "-■-"), ear swelling was observed from day 4, and the swelling increased over time. In the 5% norathyriol solution application group (dotted black diamond "...◆...") and delgocitinib application group (dashed black triangle "...▲..."), swelling was significantly suppressed, while in the betamethasone application group (dashed cross "...×..."), ear swelling was hardly observed.

[0103] Figure 2 shows a photograph of the right auricle of a mouse on day 7 of Figure 1. Figure 2(a) shows a photograph of the right auricle of one mouse from the control group, Figure 2(b) shows a photograph of the vehicle group, Figure 2(c) shows a photograph of the 5% norathyriol solution application group, Figure 2(d) shows a photograph of the betamethasone application group, and Figure 2(e) shows a photograph of the right auricle of one mouse from the delgocitinib application group. In the control group of Figure 2(a), MC903 was not applied, so no swelling of the auricle skin was observed. In the vehicle group of Figure 2(b), swelling and redness of the auricle skin were significantly observed. On the other hand, in the 5% norathyriol solution application group of Figure 2(c) and the delgocitinib application group of Figure 2(e), although some redness was observed, the redness was not as severe as in the control group, and in the betamethasone application group of Figure 2(d), no swelling or redness was observed, demonstrating a clear anti-inflammatory effect.

[0104] That is, the 5% norathyriol solution application group significantly suppressed inflammation caused by atopic dermatitis compared to the vehicle group. In other words, a composition containing norathyriol as an active ingredient can suppress inflammation caused by atopic dermatitis.

[0105] Example 2: IgE antibody production inhibitory effect Serum was collected from the mice on day 7 in Example 1, and the amount of IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IgE antibody ELISA kit (R&D).

[0106] The results are shown in Figure 3. The horizontal axis represents the sample group, and the vertical axis represents the amount of IgE antibody. In the control group without MC903 application, the IgE antibody level was 1214 ng / mL, whereas in the control group with MC903 application (labeled "vehicle"), the IgE antibody level increased significantly to 2588 ng / mL, indicating the onset of atopic dermatitis. Compared to the vehicle group, the IgE antibody production levels were significantly lower in the norathyriol-application group, the betamethasone-application group, the delgocitinib-application group, and the delgocitinib-application group: 1692 ng / mL, 1175 ng / mL, and 1812 ng / mL, respectively.

[0107] As described above, it was found that the norathyriol application group significantly suppressed the production of IgE antibodies caused by atopic dermatitis. In other words, a composition containing norathyriol as an active ingredient can suppress the production of IgE antibodies caused by atopic dermatitis.

[0108] Example 3: TSLP secretion inhibitory effect Tissues were collected from the mice on day 7 in Example 1, and the amount of TSLP secreted was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse TSLP ELISA kit (R&D).

[0109] The results are shown in Figure 4. The horizontal axis represents the sample group, and the vertical axis represents the amount of TSLP secretion. In the control group without MC903 application, the TSLP secretion level was 317 pg / mL, while in the control group with MC903 application (labeled "vehicle"), the TSLP secretion level increased significantly to 1533 pg / mL, indicating the onset of atopic dermatitis. Compared to the vehicle group, the TSLP secretion levels were 1026 pg / mL in the norathyriol application group, 651 pg / mL in the betamethasone application group, and 971 pg / mL in the delgocitinib application group. In the norathyriol application group, the betamethasone application group, and the delgocitinib application group, the TSLP secretion level was significantly reduced.

[0110] As described above, it was found that the norathyriol application group significantly suppressed TSLP secretion caused by atopic dermatitis. In other words, a composition containing norathyriol as an active ingredient can suppress TSLP secretion caused by atopic dermatitis.

[0111] Example 4: IL-4 secretion suppression effect Tissues were collected from the mice on day 7 in Example 1, and the amount of IL-4 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-4 ELISA kit (R&D).

[0112] The results are shown in Figure 5. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-4 secretion. IL-4 secretion in the control group without MC903 application was 56 pg / mL, whereas in the control group with MC903 application (labeled "vehicle"), IL-4 secretion increased significantly to 152 pg / mL, indicating the onset of atopic dermatitis. IL-4 secretion levels were significantly reduced in the norathyriol-application group and betamethasone-application group compared to the vehicle group: 94 pg / mL in the norathyriol-application group, 45 pg / mL in the betamethasone-application group, and 159 pg / mL in the delgocitinib-application group.

[0113] As described above, it was found that the norathyriol application group significantly suppressed IL-4 secretion caused by atopic dermatitis. In other words, a composition containing norathyriol as an active ingredient can suppress IL-4 secretion.

[0114] Example 5: Inhibitory effect on IL-5 secretion Tissues were collected from the mice on day 7 in Example 1, and the amount of IL-5 secreted was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse IL-5 ELISA kit (R&D).

[0115] The results are shown in Figure 6. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-5 secretion. While the MC903-unapplied control group had a IL-5 secretion level of 15 pg / mL, the MC903-applied control group (labeled "vehicle") had a significantly increased IL-5 secretion level of 32 pg / mL, indicating the onset of atopic dermatitis. Compared to the vehicle group, the norathyriol-applied group had a significantly decreased IL-5 secretion level of 14 pg / mL, the betamethasone-applied group had a significantly decreased IL-5 secretion level of 8 pg / mL, and the delgocitinib-applied group had a significantly decreased IL-5 secretion level of 33 pg / mL.

[0116] As described above, it was found that the norathyriol application group significantly suppressed IL-5 secretion caused by atopic dermatitis. In other words, a composition containing norathyriol as an active ingredient can suppress IL-5 secretion.

[0117] Example 6: Inhibitory effect on rhinitis (nose-scratching behavior) in ovalbumin-induced allergic rhinitis model mice. A 0.2 mL mixture of 50 μg ovalbumin (OVA) and 2 mg alum was administered to 6-week-old female Balb / c mice (Shimizu Experimental Materials) (day 0 of the study). Alum was used as an adjuvant. Seven and 14 days later, 0.2 mL of the mixture was again injected into the Balb / c mice for immunization. Starting on day 20, norathyriol 10 mg / kg, mangiferin 8a 10 mg / kg, tofacitinib (JAK inhibitor) 10 mg / kg, dexamethasone (steroid) 2 mg / kg, and olopatadine (antihistamine) 10 mg / kg were orally administered to the mice daily for 8 days. Furthermore, starting on day 21, 400 μg OVA was administered intranasally, and nose-scratching behavior was measured on day 27. Tofacitinib, dexamethasone, and olopatadine are currently used clinically for allergic rhinitis and were used as control drugs in this example.

[0118] The group immunized only with OVA was called the control group, those administered with norathyriol were called the norathyriol-administered group, those administered with mangiferin 8a were called the mangiferin 8a-administered group, those administered with tofacitinib were called the tofacitinib-administered group, those administered with dexamethasone were called the dexamethasone-administered group, and those administered with olopatadine were called the olopatadine-administered group. Each group consisted of five mice.

[0119] The results are shown in Figure 7. The horizontal axis represents the sample group, and the vertical axis represents the number of nose scratches. Compared to the non-OVA-immunized control, the OVA-immunized control group (indicated as "vehicle") showed a significant increase in nose scratching behavior, indicating the onset of allergic rhinitis. The norathyriol-administered group (indicated as "10 mg / kg norathyriol"), mangiferin 8a-administered group (indicated as "10 mg / kg mangiferin 8a"), tofacitinib-administered group (indicated as "10 mg / kg tofacitinib"), dexamethasone-administered group (indicated as "2 mg / kg dexamethasone"), and olopatadine-administered group (indicated as "10 mg / kg olopatadine") showed a significant decrease in the number of nose scratches compared to the vehicle group. Furthermore, the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed nose-scratching behavior compared to the tofacitinib-administered group and the olopatadine-administered group.

[0120] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed nose-scratching behavior caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress nose-scratching behavior caused by allergic rhinitis.

[0121] Example 7: Rhinitis (sneezing) suppression effect in ovalbumin-induced allergic rhinitis model mice. A 0.2 mL mixture of 50 μg ovalbumin (OVA) and 2 mg alum was administered to 6-week-old female Balb / c mice (Shimizu Experimental Materials) (day 0 of the study). Alum was used as an adjuvant. Seven and 14 days later, 0.2 mL of the mixture was again injected into the Balb / c mice for immunization. Starting on day 20, norathyriol 10 mg / kg, mangiferin 8a 10 mg / kg, tofacitinib (JAK inhibitor) 10 mg / kg, dexamethasone (steroid) 2 mg / kg, and olopatadine (antihistamine) 10 mg / kg were orally administered to the mice daily for 8 days. Furthermore, starting on day 21, 400 μg OVA was administered intranasally, and the number of sneezes was measured on day 27. Tofacitinib, dexamethasone, and olopatadine are currently used clinically for allergic rhinitis and were used as control drugs in this example.

[0122] The group not immunized with OVA is referred to as the control group ("control"), the group immunized only with OVA is referred to as the control group ("vehicle"), the group administered with norathyriol is referred to as the norathyriol-administered group ("10 mg / kg norathyriol"), the group administered with mangiferin 8a is referred to as the mangiferin 8a-administered group ("10 mg / kg mangiferin 8a"), the group administered with tofacitinib is referred to as the tofacitinib-administered group ("10 mg / kg tofacitinib"), the group administered with dexamethasone is referred to as the dexamethasone-administered group ("2 mg / kg dexamethasone"), and the group administered with olopatadine is referred to as the olopatadine-administered group ("10 mg / kg olopatadine"). Each group consisted of 5 mice.

[0123] The results are shown in Figure 8. The horizontal axis represents the sample group, and the vertical axis represents the number of sneezes. Compared with the OVA-non-immunized control, sneezing significantly increased in the OVA-immunized subject group, indicating the onset of allergic rhinitis. The norathyriol-administered group, mangiferin 8a-administered group, tofacitinib-administered group, dexamethasone-administered group, and olopatadine-administered group significantly reduced the number of sneezes compared with the vehicle group. Furthermore, the norathyriol-administered group and mangiferin 8a-administered group significantly suppressed the number of sneezes compared with the tofacitinib-administered group and olopatadine-administered group.

[0124] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed sneezing caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress sneezing caused by allergic rhinitis.

[0125] Example 8: Inhibitory effect on OVA-IgE antibody production Serum was collected from the mice on day 28 in Examples 6 and 7, and the amount of OVA-IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse OVA-IgE antibody ELISA kit (FUJIFILM WAKO).

[0126] The results are shown in Figure 9. The horizontal axis represents the sample group, and the vertical axis represents the amount of OVA-IgE antibody. While the non-OVA-immunized control group had an OVA-IgE antibody level of 2.7 U / mL, the OVA-immunized subject group (labeled "vehicle") had an OVA-IgE antibody level that significantly increased to 69 U / mL, indicating the onset of allergic rhinitis. Compared to the vehicle group, the OVA-IgE antibody production levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively. Furthermore, the norathyriol-administered group and mangiferin 8a-administered group significantly suppressed OVA-IgE antibody production compared with the tofacitinib-administered group and olopatadine-administered group.

[0127] As described above, it was found that the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed the production of OVA-IgE antibodies caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress the production of OVA-IgE antibodies caused by allergic rhinitis.

[0128] Example 9: IgE antibody production inhibitory effect Serum was collected from the mice on day 28 in Examples 6 and 7, and the amount of IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IgE antibody ELISA kit (R&D).

[0129] The results are shown in Figure 10. The horizontal axis represents the sample group, and the vertical axis represents the amount of IgE antibody. The non-OVA control group had an IgE antibody level of 58 ng / mL, whereas the OVA-immunized control group (labeled "vehicle") had an IgE antibody level of 111 ng / mL, indicating the onset of allergic rhinitis. Compared to the vehicle group, the IgE antibody production levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IgE antibody production compared to the tofacitinib administration group and the olopatadine administration group.

[0130] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed the production of IgE antibodies caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress the production of IgE antibodies caused by allergic rhinitis.

[0131] Example 10: Inhibitory effect on BAFF secretion Serum was collected from the mice on day 28 in Examples 6 and 7, and the amount of BAFF secretion was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse BAFF ELISA kit (R&D).

[0132] The results are shown in Figure 11. The horizontal axis represents the sample group, and the vertical axis represents the amount of BAFF secretion. While the non-OVA-immunized control group had a BAFF secretion level of 157 pg / mL, the OVA-immunized control group (labeled "vehicle") had a significantly increased BAFF secretion level of 1,450 pg / mL, indicating the onset of allergic rhinitis. Compared to the vehicle group, the BAFF secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 629 pg / mL, 668 pg / mL, 1041 pg / mL, 266 pg / mL, and 1691 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed BAFF secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0133] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed BAFF secretion caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress BAFF secretion caused by allergic rhinitis.

[0134] Example 11: IL-4 secretion suppression effect Serum was collected from the mice on day 28 in Examples 6 and 7, and the amount of IL-4 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-4 ELISA kit (R&D).

[0135] The results are shown in Figure 12. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-4 secretion. While the non-OVA-immunized control group had an IL-4 secretion level of 227 pg / mL, the OVA-immunized control group (labeled "vehicle") had an IL-4 secretion level that was significantly increased to 872 pg / mL, indicating the onset of allergic rhinitis. Compared to the vehicle group, the IL-4 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 495 pg / mL, 468 pg / mL, 808 pg / mL, 336 pg / mL, and 717 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-4 secretion compared with the tofacitinib administration group and the olopatadine administration group.

[0136] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-4 secretion caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-4 secretion caused by allergic rhinitis.

[0137] Example 12: Inhibitory effect on IL-5 secretion Serum was collected from the mice on day 28 in Examples 6 and 7, and the amount of IL-5 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-5 ELISA kit (R&D).

[0138] The results are shown in Figure 13. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-5 secretion. While the non-OVA-immunized control group had an IL-5 secretion level of 151 pg / mL, the OVA-immunized subject group (labeled "vehicle") had an IL-5 secretion level that was significantly increased to 1010 pg / mL, indicating the onset of allergic rhinitis. Compared to the vehicle group, the IL-5 secretion levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively, at 633 pg / mL, 675 pg / mL, 839 pg / mL, 314 pg / mL, and 880 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-5 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0139] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-5 secretion caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-5 secretion caused by allergic rhinitis.

[0140] Example 13: Inhibitory effect on IL-17 secretion Serum was collected from the mice on day 28 in Examples 6 and 7, and the amount of IL-17 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-17 ELISA kit (R&D).

[0141] The results are shown in Figure 14. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-17 secretion. While the non-OVA-immunized control group had an IL-17 secretion level of 204 pg / mL, the OVA-immunized subject group (labeled "vehicle") had an IL-17 secretion level that was significantly increased to 945 pg / mL, indicating the onset of allergic rhinitis. Compared to the vehicle group, the IL-17 secretion levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively, at 583 pg / mL, 557 pg / mL, 892 pg / mL, 227 pg / mL, and 839 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-17 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0142] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-17 secretion caused by allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-17 secretion caused by allergic rhinitis.

[0143] That is, from the results of Examples 6-13, it can be said that the control group developed allergic rhinitis, while the norathyriol administration group and the mangiferin 8a administration group suppressed allergic rhinitis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress allergic rhinitis.

[0144] Example 14: Cough suppression effect in ovalbumin-induced bronchial asthma model mice. A 0.2 mL mixture of 50 μg ovalbumin (OVA) and 2 mg alum was administered to 6-week-old female Balb / c mice (Shimizu Experimental Materials) (day 0 of the study). Alum was used as an adjuvant. Seven and 14 days later, 0.2 mL of the mixture was injected into the Balb / c mice again for immunization. Starting on day 20, norathyriol 10 mg / kg, mangiferin 8a 10 mg / kg, tofacitinib (JAK inhibitor) 10 mg / kg, dexamethasone (steroid) 2 mg / kg, and olopatadine (antihistamine) 10 mg / kg were orally administered to the mice daily for 8 days. Furthermore, starting on day 21, 400 μg OVA was administered intranasally, and the number of coughs was measured on day 27. Tofacitinib, dexamethasone, and olopatadine are currently used clinically for bronchial asthma and were used as control drugs in this example.

[0145] The group immunized only with OVA was called the control group, those administered with norathyriol were called the norathyriol-administered group, those administered with mangiferin 8a were called the mangiferin 8a-administered group, those administered with tofacitinib were called the tofacitinib-administered group, those administered with dexamethasone were called the dexamethasone-administered group, and those administered with olopatadine were called the olopatadine-administered group. Each group consisted of five mice.

[0146] The results are shown in Figure 15. The horizontal axis represents the sample group, and the vertical axis represents the number of coughs. Compared with the non-OVA-immunized control, the OVA-immunized control group (indicated as "vehicle") showed a significant increase in coughs, indicating the onset of bronchial asthma. The norathyriol-administered group (indicated as "10 mg / kg norathyriol"), mangiferin 8a-administered group (indicated as "10 mg / kg mangiferin 8a"), and dexamethasone-administered group (indicated as "2 mg / kg dexamethasone") showed a significant decrease in the number of coughs compared with the vehicle group. Furthermore, the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed cough compared to the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib") and the olopatadine-administered group (denoted as "10 mg / kg olopatadine").

[0147] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed cough caused by bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress cough caused by bronchial asthma.

[0148] Example 15: Inhibitory effect on OVA-IgE antibody production Serum was collected from the mice on day 28 in Example 14, and the amount of OVA-IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse OVA-IgE antibody ELISA kit (FUJIFILM WAKO).

[0149] The results are shown in Figure 16. The horizontal axis represents the sample group, and the vertical axis represents the amount of OVA-IgE antibody. While the non-OVA-immunized control group had an OVA-IgE antibody level of 2.4 U / mL, the OVA-immunized subject group (labeled "vehicle") had an OVA-IgE antibody level of 66 U / mL, which is a significant increase, indicating the onset of bronchial asthma. The OVA-IgE antibody production levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), compared to the vehicle group. Furthermore, the norathyriol-administered group and mangiferin 8a-administered group significantly suppressed OVA-IgE antibody production compared with the tofacitinib-administered group and olopatadine-administered group.

[0150] As described above, it was found that the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed the production of OVA-IgE antibodies caused by bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress the production of OVA-IgE antibodies caused by bronchial asthma.

[0151] Example 16: IgE antibody production inhibitory effect Serum was collected from the mice on day 28 in Example 14, and the amount of IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IgE antibody ELISA kit (R&D).

[0152] The results are shown in Figure 17. The horizontal axis represents the sample group, and the vertical axis represents the amount of IgE antibody. The non-OVA control group had an IgE antibody level of 73 ng / mL, whereas the OVA-immunized control group (labeled "vehicle") had an IgE antibody level of 117 ng / mL, indicating the onset of bronchial asthma. Compared to the vehicle group, the IgE antibody production levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IgE antibody production compared to the tofacitinib administration group and the olopatadine administration group.

[0153] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed the production of IgE antibodies caused by bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress the production of IgE antibodies caused by bronchial asthma.

[0154] Example 17: Inhibitory effect on BAFF secretion Serum was collected from the mice on day 28 in Example 14, and the amount of BAFF secretion was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse BAFF ELISA kit (R&D).

[0155] The results are shown in Figure 18. The horizontal axis represents the sample group, and the vertical axis represents the amount of BAFF secretion. While the non-OVA-immunized control group had a BAFF secretion level of 97 pg / mL, the OVA-immunized control group (labeled "vehicle") had a significantly increased BAFF secretion level of 1,319 pg / mL, indicating the onset of bronchial asthma. Compared to the vehicle group, the BAFF secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 649 pg / mL, 708 pg / mL, 902 pg / mL, 321 pg / mL, and 1304 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed BAFF secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0156] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed BAFF secretion caused by bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress BAFF secretion caused by bronchial asthma.

[0157] Example 18: IL-4 secretion suppression effect Serum was collected from the mice on day 28 in Example 14, and the amount of IL-4 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-4 ELISA kit (R&D).

[0158] The results are shown in Figure 19. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-4 secretion. While the non-OVA-immunized control group had an IL-4 secretion level of 282 pg / mL, the OVA-immunized control group (labeled "vehicle") had an IL-4 secretion level that was significantly increased to 863 pg / mL, indicating the onset of bronchial asthma. Compared to the vehicle group, the IL-4 secretion levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively, at 545 pg / mL, 617 pg / mL, 831 pg / mL, 359 pg / mL, and 781 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-4 secretion compared with the tofacitinib administration group and the olopatadine administration group.

[0159] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-4 secretion caused by bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-4 secretion caused by bronchial asthma.

[0160] Example 19: IL-5 secretion suppression effect Serum was collected from the mice on day 28 in Example 14, and the amount of IL-5 secretion was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-5 ELISA kit (R&D).

[0161] The results are shown in Figure 20. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-5 secretion. While the non-OVA-immunized control group had an IL-5 secretion level of 80 pg / mL, the OVA-immunized control group (labeled "vehicle") had an IL-5 secretion level that was significantly increased to 992 pg / mL, indicating the onset of bronchial asthma. Compared to the vehicle group, the IL-5 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-5 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0162] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-5 secretion caused by bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-5 secretion caused by bronchial asthma.

[0163] Example 20: Inhibitory effect on IL-17 secretion Serum was collected from the mice on day 28 in Example 14, and the amount of IL-17 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-17 ELISA kit (R&D).

[0164] The results are shown in Figure 21. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-17 secretion. While the non-OVA-immunized control group had an IL-17 secretion level of 80 pg / mL, the OVA-immunized subject group (labeled "vehicle") had an IL-17 secretion level that significantly increased to 898 pg / mL, indicating the onset of bronchial asthma. Compared to the vehicle group, the IL-17 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 530 pg / mL, 592 pg / mL, 844 pg / mL, 257 pg / mL, and 848 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-17 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0165] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-17 secretion caused by bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-17 secretion caused by bronchial asthma.

[0166] That is, from the results of Examples 14 to 20, it can be said that the control group developed bronchial asthma, while the norathyriol administration group and the mangiferin 8a administration group suppressed bronchial asthma. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress bronchial asthma.

[0167] Example 21: Diarrhea suppression effect in ovalbumin-induced food allergy model mice. A 0.2 mL mixture of 10 μg ovalbumin (OVA) and 1 mg alum was administered to 6-week-old female Balb / c mice (Shimizu Experimental Materials) (day 0 of the study). Alum was used as an adjuvant. Seven days later, 0.2 mL of the mixture was injected into the Balb / c mice for immunization. Starting on day 14, norathyriol was orally administered at 10 mg / kg, mangiferin 8a at 10 mg / kg, tofacitinib (JAK inhibitor) at 10 mg / kg, dexamethasone (steroid) at 2 mg / kg, and olopatadine (antihistamine) at 10 mg / kg daily for 14 days. Furthermore, 10 mg OVA was orally administered every other day from day 14 until day 21, and the frequency of diarrhea was measured after the final administration on day 28. Tofacitinib, dexamethasone, and olopatadine are currently used clinically for food allergies and were used as control drugs in this example.

[0168] The group immunized only with OVA was called the control group, those administered with norathyriol were called the norathyriol-administered group, those administered with mangiferin 8a were called the mangiferin 8a-administered group, those administered with tofacitinib were called the tofacitinib-administered group, those administered with dexamethasone were called the dexamethasone-administered group, and those administered with olopatadine were called the olopatadine-administered group. Each group consisted of five mice.

[0169] The results are shown in Figure 22. The horizontal axis indicates the sample group, and the vertical axis indicates the frequency of diarrhea (%). Compared with the non-OVA-immunized control, the frequency of diarrhea in the OVA-immunized control group (indicated as "vehicle") was significantly increased, indicating the onset of food allergy. The frequency of diarrhea was significantly reduced in the norathyriol-administered group (indicated as "10 mg / kg norathyriol"), mangiferin 8a-administered group (indicated as "10 mg / kg mangiferin 8a"), and dexamethasone-administered group (indicated as "2 mg / kg dexamethasone") compared with the vehicle group. Furthermore, the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed the occurrence of diarrhea compared to the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib") and the olopatadine-administered group (denoted as "10 mg / kg olopatadine").

[0170] As described above, it was found that diarrhea caused by food allergy was significantly suppressed in the norathyriol-administered group and the mangiferin 8a-administered group. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress diarrhea caused by food allergy.

[0171] Example 22: Inhibitory effect on OVA-IgE antibody production Serum was collected from the mice on day 28 in Example 21, and the amount of OVA-IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse OVA-IgE antibody ELISA kit (FUJIFILM WAKO).

[0172] The results are shown in Figure 23. The horizontal axis represents the sample group, and the vertical axis represents the amount of OVA-IgE antibody. While the non-OVA-immunized control group had an OVA-IgE antibody level of 1.5 U / mL, the OVA-immunized control group (labeled "vehicle") had an OVA-IgE antibody level of 74 U / mL, a significant increase that indicates the onset of food allergy. Compared to the vehicle group, the OVA-IgE antibody production levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively, at 45 U / mL, 40 U / mL, 61 U / mL, 21 U / mL, and 68 U / mL, respectively. Furthermore, the norathyriol-administered group and mangiferin 8a-administered group significantly suppressed OVA-IgE antibody production compared with the tofacitinib-administered group and olopatadine-administered group.

[0173] As described above, it was found that the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed the production of OVA-IgE antibodies caused by food allergies. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress the production of OVA-IgE antibodies caused by food allergies.

[0174] Example 23: IgE antibody production inhibitory effect Serum was collected from the mice on day 28 in Example 21, and the amount of IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IgE antibody ELISA kit (R&D).

[0175] The results are shown in Figure 24. The horizontal axis represents the sample group, and the vertical axis represents the amount of IgE antibody. The non-OVA control group had an IgE antibody level of 56 ng / mL, whereas the OVA-immunized control group (labeled "vehicle") had an IgE antibody level of 124 ng / mL, indicating the onset of food allergy. Compared to the vehicle group, the IgE antibody production levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IgE antibody production compared to the tofacitinib administration group and the olopatadine administration group.

[0176] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed the production of IgE antibodies caused by food allergies. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress the production of IgE antibodies caused by food allergies.

[0177] Example 24: Inhibitory effect on BAFF secretion Serum was collected from the mice on day 28 in Example 21, and the amount of BAFF secretion was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse BAFF ELISA kit (R&D).

[0178] The results are shown in Figure 25. The horizontal axis represents the sample group, and the vertical axis represents the amount of BAFF secretion. While the non-OVA-immunized control group had a BAFF secretion level of 134 pg / mL, the OVA-immunized control group (labeled "vehicle") had a significantly increased BAFF secretion level of 845 pg / mL, indicating the onset of food allergy. Compared to the vehicle group, the BAFF secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 426 pg / mL, 398 pg / mL, 598 pg / mL, 251 pg / mL, and 715 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed BAFF secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0179] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed BAFF secretion caused by food allergy. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress BAFF secretion caused by food allergy.

[0180] Example 25: IL-4 secretion suppression effect Serum was collected from the mice on day 28 in Example 21, and the amount of IL-4 secretion was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-4 ELISA kit (R&D).

[0181] The results are shown in Figure 26. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-4 secreted. While the non-OVA-immunized control group had an IL-4 secretion level of 210 pg / mL, the OVA-immunized control group (labeled "vehicle") had a significantly increased IL-4 secretion level of 1154 pg / mL, indicating the onset of food allergy. Compared to the vehicle group, the IL-4 secretion levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively, at 694 pg / mL, 648 pg / mL, 1015 pg / mL, 415 pg / mL, and 1054 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-4 secretion compared with the tofacitinib administration group and the olopatadine administration group.

[0182] As described above, it was found that the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed IL-4 secretion caused by food allergy. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-4 secretion caused by food allergy.

[0183] Example 26: IL-5 secretion suppression effect Serum was collected from the mice on day 28 in Example 21, and the amount of IL-5 secretion was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-5 ELISA kit (R&D).

[0184] The results are shown in Figure 27. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-5 secreted. While the non-OVA-immunized control group had an IL-5 secretion level of 135 pg / mL, the OVA-immunized control group (labeled "vehicle") had an IL-5 secretion level that was significantly increased to 916 pg / mL, indicating the onset of food allergy. Compared to the vehicle group, the IL-5 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 475 pg / mL, 487 pg / mL, 791 pg / mL, 249 pg / mL, and 832 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-5 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0185] As described above, it was found that the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed IL-5 secretion caused by food allergy. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-5 secretion caused by food allergy.

[0186] Example 27: IL-17 secretion-inhibitory effect Serum was collected from the mice on day 28 in Example 21, and the amount of IL-17 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-17 ELISA kit (R&D).

[0187] The results are shown in Figure 28. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-17 secreted. While the non-OVA-immunized control group had an IL-17 secretion level of 98 pg / mL, the OVA-immunized control group (labeled "vehicle") had an IL-17 secretion level that was significantly increased to 875 pg / mL, indicating the onset of food allergy. Compared to the vehicle group, the IL-17 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 451 pg / mL, 467 pg / mL, 741 pg / mL, 216 pg / mL, and 721 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-17 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0188] As described above, it was found that the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed IL-17 secretion caused by food allergy. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-17 secretion caused by food allergy.

[0189] That is, from the results of Examples 21 to 27, it can be said that the control group developed food allergy, while the norathyriol administration group and the mangiferin 8a administration group suppressed food allergy. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress food allergy.

[0190] Example 28: Inhibitory effect on rhinitis (nose-scratching behavior) in cedar pollinosis model mice. A mixture of 100 μg cedar pollen and 1 mg alum was administered in 0.2 mL to 6-week-old female Balb / c mice (Shimizu Experimental Materials) (day 0 of the study). Alum was used as an adjuvant. Seven and 14 days later, 0.2 mL of the mixture was again injected into the Balb / c mice for immunization. Starting on day 20, norathyriol was orally administered at 10 mg / kg, mangiferin 8a at 10 mg / kg, tofacitinib (JAK inhibitor) at 10 mg / kg, dexamethasone (steroid) at 2 mg / kg, and olopatadine (antihistamine) at 10 mg / kg daily for 8 days. Furthermore, starting on day 21, 500 μg cedar pollen was administered by nasal instillation, and nose-scratching behavior was measured on day 27. Tofacitinib, dexamethasone, and olopatadine are currently used clinically for the treatment of hay fever, and were used as control drugs in this example.

[0191] The group immunized only with cedar pollen was called the control group, those administered norathyriol were called the norathyriol administration group, those administered mangiferin 8a were called the mangiferin 8a administration group, those administered tofacitinib were called the tofacitinib administration group, those administered dexamethasone were called the dexamethasone administration group, and those administered olopatadine were called the olopatadine administration group.Each group consisted of 5 mice.

[0192] The results are shown in Figure 29. The horizontal axis represents the sample group, and the vertical axis represents the number of nose-scratching episodes. Compared to the control group not immunized with cedar pollen, the cedar pollen-immunized control group (indicated as "vehicle") showed a significant increase in nose-scratching behavior, indicating the onset of cedar pollinosis. The norathyriol-administered group (indicated as "10 mg / kg norathyriol"), mangiferin 8a-administered group (indicated as "10 mg / kg mangiferin 8a"), tofacitinib-administered group (indicated as "10 mg / kg tofacitinib"), dexamethasone-administered group (indicated as "2 mg / kg dexamethasone"), and olopatadine-administered group (indicated as "10 mg / kg olopatadine") showed a significant decrease in the number of nose-scratching episodes compared to the vehicle group. Furthermore, the norathyriol-administered group and the mangiferin 8a-administered group significantly suppressed nose-scratching behavior compared to the tofacitinib-administered group and the olopatadine-administered group.

[0193] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed nose-scratching behavior caused by cedar pollinosis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress nose-scratching behavior caused by cedar pollinosis.

[0194] Example 29: Suppression of rhinitis (sneezing) in cedar pollinosis model mice A mixture of 100 μg cedar pollen and 1 mg alum was administered in 0.2 mL to 6-week-old female Balb / c mice (Shimizu Experimental Materials) (day 0 of the study). Alum was used as an adjuvant. Seven and 14 days later, 0.2 mL of the mixture was injected again into the Balb / c mice for immunization. Starting on day 20, norathyriol was orally administered at 10 mg / kg, mangiferin 8a at 10 mg / kg, tofacitinib (JAK inhibitor) at 10 mg / kg, dexamethasone (steroid) at 2 mg / kg, and olopatadine (antihistamine) at 10 mg / kg daily for 8 days. Furthermore, starting on day 21, 500 μg cedar pollen was administered by nasal instillation, and the number of sneezes was measured on day 27. Tofacitinib, dexamethasone, and olopatadine are currently used clinically for the treatment of hay fever, and were used as control drugs in this example.

[0195] The group not immunized with cedar pollen is called the control group (denoted as "control"), the group immunized only with cedar pollen is called the control group (denoted as "vehicle"), the group administered norathyriol is called the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the group administered mangiferin 8a is called the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the group administered tofacitinib is called the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the group administered dexamethasone is called the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the group administered olopatadine is called the olopatadine-administered group (denoted as "10 mg / kg olopatadine"). Each group consisted of 5 animals.

[0196] The results are shown in Figure 30. The horizontal axis represents the sample group, and the vertical axis represents the number of sneezes. Compared with the control group not immunized with cedar pollen, sneezing significantly increased in the subject group immunized with cedar pollen, indicating the onset of cedar pollinosis. Compared with the vehicle group, the norathyriol-administered group, mangiferin 8a-administered group, tofacitinib-administered group, dexamethasone-administered group, and olopatadine-administered group showed a significant decrease in the number of sneezes. Furthermore, the norathyriol-administered group and mangiferin 8a-administered group showed a significant suppression of the number of sneezes compared with the tofacitinib-administered group and olopatadine-administered group.

[0197] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed sneezing caused by cedar pollinosis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress sneezing caused by cedar pollinosis.

[0198] Example 30: IgE antibody production inhibitory effect Serum was collected from the mice on day 28 in Examples 28 and 29, and the amount of IgE antibody produced was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IgE antibody ELISA kit (R&D).

[0199] The results are shown in Figure 31. The horizontal axis represents the sample group, and the vertical axis represents the amount of IgE antibody. The non-cedar pollen-immunized control group had an IgE antibody level of 71 ng / mL, whereas the cedar pollen-immunized subject group (labeled "vehicle") had a significantly increased IgE antibody level of 207 ng / mL, indicating the onset of cedar pollinosis. Compared to the vehicle group, the IgE antibody production levels were significantly reduced in the norathyriol-administered group (denoted as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (denoted as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (denoted as "10 mg / kg tofacitinib"), the dexamethasone-administered group (denoted as "2 mg / kg dexamethasone"), and the olopatadine-administered group (denoted as "10 mg / kg olopatadine"), respectively, at 156 ng / mL, 139 ng / mL, 185 ng / mL, 154 ng / mL, and 218 ng / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IgE antibody production compared to the tofacitinib administration group and the olopatadine administration group.

[0200] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed the production of IgE antibodies caused by cedar pollinosis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress the production of IgE antibodies caused by cedar pollinosis.

[0201] Example 31: IL-4 secretion suppression effect Serum was collected from the mice on day 28 in Examples 28 and 29, and the amount of IL-4 secretion was measured by enzyme-linked immunosorbent assay (ELISA). The measurement was performed using a mouse IL-4 ELISA kit (R&D).

[0202] The results are shown in Figure 32. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-4 secretion. In the control group not immunized with cedar pollen, the level was 55 pg / mL, whereas in the subject group immunized with cedar pollen (labeled "vehicle"), the level of IL-4 secretion was significantly increased to 374 pg / mL, indicating the onset of cedar pollinosis. Compared to the vehicle group, the IL-4 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 111 pg / mL, 90 pg / mL, 213 pg / mL, 78 pg / mL, and 263 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-4 secretion compared with the tofacitinib administration group and the olopatadine administration group.

[0203] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-4 secretion caused by cedar pollinosis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-4 secretion caused by cedar pollinosis.

[0204] Example 32: Inhibitory effect on IL-5 secretion Serum was collected from the mice on day 28 in Examples 28 and 29, and the amount of IL-5 secreted was measured by enzyme-linked immunosorbent assay (ELISA). The measurement was performed using a mouse IL-5 ELISA kit (R&D).

[0205] The results are shown in Figure 33. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-5 secreted. In the control group not immunized with cedar pollen, the level was 77 pg / mL, whereas in the subject group immunized with cedar pollen (labeled "vehicle"), the level of IL-5 secreted was significantly increased to 708 pg / mL, indicating the onset of cedar pollinosis. Compared to the vehicle group, the IL-5 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 307 pg / mL, 300 pg / mL, 428 pg / mL, 182 pg / mL, and 438 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-5 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0206] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-5 secretion caused by cedar pollinosis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-5 secretion caused by cedar pollinosis.

[0207] Example 33: Inhibitory effect on IL-17 secretion Serum was collected from the mice on day 28 in Examples 28 and 29, and the amount of IL-17 secreted was measured by enzyme-linked immunosorbent assay (ELISA). The measurement was performed using a mouse IL-17 ELISA kit (R&D).

[0208] The results are shown in Figure 34. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-17 secretion. In the control group not immunized with cedar pollen, the level was 18 pg / mL, whereas in the subject group immunized with cedar pollen (labeled "vehicle"), the level of IL-17 secretion was significantly increased to 397 pg / mL, indicating the onset of cedar pollinosis. Compared to the vehicle group, the IL-17 secretion levels were significantly reduced in the norathyriol-administered group (referred to as "10 mg / kg norathyriol"), the mangiferin 8a-administered group (referred to as "10 mg / kg mangiferin 8a"), the tofacitinib-administered group (referred to as "10 mg / kg tofacitinib"), the dexamethasone-administered group (referred to as "2 mg / kg dexamethasone"), and the olopatadine-administered group (referred to as "10 mg / kg olopatadine"), respectively, at 195 pg / mL, 190 pg / mL, 244 pg / mL, 49 pg / mL, and 172 pg / mL, respectively. Furthermore, the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-17 secretion compared to the tofacitinib administration group and the olopatadine administration group.

[0209] As described above, it was found that the norathyriol administration group and the mangiferin 8a administration group significantly suppressed IL-17 secretion caused by cedar pollinosis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress IL-17 secretion caused by cedar pollinosis.

[0210] That is, from the results of Examples 28 to 33, it can be said that the control group developed cedar pollinosis, while the norathyriol administration group and the mangiferin 8a administration group suppressed cedar pollinosis. In other words, a composition containing norathyriol or mangiferin 8a as an active ingredient can suppress cedar pollinosis.

[0211] Example 34: Inhibitory effect on differentiation into mature B cells B cells collected from mice were cultured for one day in RPMI 1640 medium. Subsequently, 100 μM mangiferin, 10 μM mangiferin 8a, 10 μM norathyriol, 20 μM 1,3,5,6-tetrahydroxyxanthone, 10 μM xanthohydrol, 10 μM α-mangostin, and 10 μM γ-mangostin were added to separate B cells. After one day of culture, 100 ng / mL BAFF was added and the cells were cultured for 10 days. After 10 days of culture, the cells were stained with anti-IgM and anti-IgD antibodies, which are B cell markers, and the expression of IgM and IgD was measured using a BD LSRFortessa. IgM-negative and IgD-negative indicate pre-B cells, IgM-positive and IgD-negative indicate immature B cells, and IgM-positive and IgD-positive indicate mature B cells.

[0212] The results are shown in Figures 35, 36, and 37. In each figure, the horizontal axis represents the expression level of IgM, and the vertical axis represents the expression level of IgD. In the control group (Figure 35(a)) to which no compound or BAFF was added, the IgM-negative / IgD-negative population was 99.5%, the IgM-positive / IgD-negative population was 0.529%, and the IgM-positive / IgD-positive population was 0%, whereas in the BAFF-added group (Figure 35(b)), the IgM-negative / IgD-negative population was 11.7%, the IgM-positive / IgD-negative population was 42.3%, and the IgM-positive / IgD-positive population was 45.6%, demonstrating differentiation into mature B cells.

[0213] In the mangiferin administration group (Fig. 35(c)), the IgM-negative IgD-negative population was 95.8%, the IgM-positive IgD-negative population was 3.24%, and the IgM-positive IgD-positive population was 0.00%. In the mangiferin 8a administration group (Fig. 36(d)), the IgM-negative IgD-negative population was 98.3%, the IgM-positive IgD-negative population was 1.67%, and the IgM-positive IgD-positive population was 0.00%. In the norathyriol-administered group (Fig. 36(e)), the IgM-negative and IgD-negative population was 98.5%, the IgM-positive and IgD-negative population was 1.46%, and the IgM-positive and IgD-positive population was 0.062%. In the 1,3,5,6-tetrahydroxyxanthone-administered group (Fig. 36(f)), the IgM-negative and IgD-negative population was 96.5%, the IgM-positive and IgD-negative population was 0.062%. In the xanthohydrol administration group (Figure 37(g)), the IgM negative IgD negative population was 96.3%, the IgM positive IgD negative population was 3.64%, and the IgM positive IgD positive population was 0%. In the α-mangostin administration group (Figure 37(h)), the IgM negative IgD negative population was 78.1%, The IgM-positive IgD-negative population was 21.2%, the IgM-positive IgD-positive population was 0.363%, and in the γ-mangostin-administered group (Figure 37(i)), the IgM-negative IgD-negative population was 79.7%, the IgM-positive IgD-negative population was 19.7%, and the IgM-positive IgD-positive population was 0.561%, showing a significant decrease in the proportion of mature B cells with both drugs.

[0214] That is, it was found that mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin inhibit the differentiation of pre-B cells into mature B cells in allergic inflammation caused by BAFF.

[0215] Example 35: Inhibitory effect on plasma cell differentiation B cells collected from mice were cultured for one day in RPMI 1640 medium. Subsequently, 100 μM mangiferin, 10 μM mangiferin 8a, 10 μM norathyriol, 20 μM 1,3,5,6-tetrahydroxyxanthone, 10 μM xanthohydrol, 10 μM α-mangostin, and 10 μM γ-mangostin were added to separate B cells. After one day of culture, 100 ng / mL BAFF was added, followed by 10 days of culture. After 10 days of culture, the cells were stained with anti-CD138 antibody, a plasma cell marker, and CD138 expression was measured using a BD LSRFortessa.

[0216] The results are shown in Figures 38, 39, and 40. In each figure, the horizontal axis represents the expression level of CD138, and the vertical axis represents the cell number. The solid line in each panel represents a control containing neither BAFF nor compound, the dotted line represents cells containing 100 ng / mL BAFF (100 ng / mL BAFF was simply added to B cells), and the dashed line represents cells containing 100 ng / mL BAFF and each compound. Compared to the control containing no compound or BAFF, CD138 expression was significantly increased in the BAFF-added group.

[0217] In the mangiferin administration group (Figure 38(a)), mangiferin 8a administration group (Figure 38(b)), norathyriol administration group (Figure 38(c)), 1,3,5,6-tetrahydroxyxanthone administration group (Figure 39(d)), xanthohydrol administration group (Figure 39(e)), α-mangostin administration group (Figure 40(f)), and γ-mangostin administration group (Figure 40(g)), the CD138 expression level was significantly reduced compared to the BAFF-added group, and was almost the same as the control. In other words, it was found that mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin suppress the differentiation into plasma cells in BAFF-induced allergic inflammation.

[0218] Example 36: Inhibitory effect of compounds on NIK activity in B cells stimulated with BAFF Spleens were collected from 6-week-old male Balb / c mice, and B cells were isolated.2 The control was a dish containing 100 mm B cells and cultured in RPMI 1640 medium for 1 day. 2 After culturing for 1 day, 100 ng / mL BAFF was added and the resulting culture was incubated for 1 hour. This was designated as "100 ng / mL BAFF." 2 The cells were seeded on a dish and cultured for one day. Then, 100 μM mangiferin, 10 μM mangiferin 8a, 10 μM norathyriol, 20 μM 1,3,5,6-tetrahydroxyxanthone, 10 μM xanthohydrol, 10 μM α-mangostin, and 10 μM γ-mangostin were added to each of the B cells. After 23 hours, 100 ng / mL BAFF was added to each of the B cells, and the cells were cultured for one hour. All the B cells were cultured at 37°C and 5% CO. 2 The cells were cultured under the conditions.

[0219] Proteins were extracted from the cell lysate and used as samples. Each sample was subjected to SDS-PAGE, transferred to a PVDF membrane, and assayed using anti-phospho-NIK antibody, anti-NIK antibody, anti-NF-κB p52 antibody, anti-NF-κB p65 antibody, and anti-Lamin antibody.

[0220] The results of immunoblotting are shown in Figure 41. The horizontal axis shows the groups administered with mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin as reagents (compounds).

[0221] The vertical axis indicates the type of antibody, specifically, anti-phospho-NIK antibody (denoted as "Phospho-NIK"), anti-NIK antibody (denoted as "NIK"), anti-NF-κBp52 antibody (denoted as "NF-κBp52nuclear"), anti-NF-κBp65 antibody (denoted as "NF-κBp65nuclear"), and anti-Lamin antibody (denoted as "Lamin").

[0222] In the photograph of the anti-NIK antibody, no decrease in the intensity of the NIK band was observed compared to the control. In the case of the anti-phospho-NIK antibody, the intensity increased at 100 ng / mL BAFF compared to the control. This indicates that the addition of BAFF activates NIK and enhances the differentiation and activation of B cells.

[0223] On the other hand, in the case of anti-phospho-NIK antibody, the immunoblotting results of the samples containing mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin were weak. Therefore, it can be said that mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin inhibit the phosphorylation of NIK.

[0224] Next, we will look at the anti-NF-κBp52 antibody (referred to as "NF-κBp52nuclear"), anti-NF-κBp65 antibody (referred to as "NF-κBp65nuclear"), and anti-Lamin antibody (referred to as "Lamin") against intranuclear substances. Lamin was present regardless of the compounds, but it was confirmed that intranuclear NF-κBp52 was lighter with the administration of mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin compared to 100 ng / mL BAFF. In addition, intranuclear NF-κBp65 was also reduced (lighter shade) with all compounds compared to 100 ng / mL BAFF.

[0225] Lamin is a fibrous protein that maintains structure and regulates transcription within the cell nucleus, and was detected as an internal standard (loading control) for nuclear proteins. Therefore, when the loading control for nuclear proteins was detected in all samples, the addition of each compound indicated that NF-κB p65 and NF-κB p52 were absent or present in very small amounts within the nucleus. In other words, mangiferin, mangiferin 8a, norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthohydrol, α-mangostin, and γ-mangostin are NIK inhibitors.

[0226] Example 37: Inhibitory effect on TNFα secretion upon BAFF stimulation Spleens were collected from 6-week-old male DBA / 1J mice, and B cells were isolated. After isolation, the cells were cultured in RPMI 1640 medium for 1 day. 10 μM mangiferin 8a and 10 μM norathyriol were then added to separate B cells. After 3 hours, 100 ng / mL BAFF was added to each B cell, and the cells were cultured for 7 days. After 7 days of culture, the culture supernatant was collected, and the amount of TNFα secreted was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse TNFα ELISA kit (R&D).

[0227] The results are shown in Figure 42. The horizontal axis represents the sample group, and the vertical axis represents the amount of TNFα secreted (pg / mL). In the control (neither compound nor BAFF was added), TNFα was 11.34 pg / mL, whereas in the 100 ng / mL BAFF (B cells to which only 100 ng / mL BAFF was added), TNFα was 230.64 pg / mL, indicating that BAFF stimulation activated B cells and enhanced TNFα secretion.

[0228] On the other hand, the values ​​in the mangiferin 8a administration group and the norathyriol administration group were 41.88 pg / mL and 45.07 pg / mL, respectively.

[0229] As described above, it was found that administration of mangiferin 8a and norathyriol significantly suppresses BAFF-stimulated TNFα secretion. As a result, it can be said that excessive TNFα is suppressed and allergic diseases are improved.

[0230] Example 38: Inhibitory effect on IL-6 secretion upon BAFF stimulation Spleens were collected from 6-week-old male DBA / 1J mice, and B cells were isolated. After isolation, the cells were cultured for 1 day in RPMI 1640 medium. 10 μM mangiferin 8a and 10 μM norathyriol were then added to separate B cells. After 3 hours, 100 ng / mL BAFF was added to each B cell, followed by culture for 7 days. After 7 days of culture, the culture supernatant was collected, and the amount of IL-6 secreted was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse IL-6 ELISA kit (R&D).

[0231] The results are shown in Figure 43. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-6 secretion (pg / mL). In the control (neither compound nor BAFF was added), IL-6 was 26.06 pg / mL, whereas in the 100 ng / mL BAFF (B cells to which only 100 ng / mL BAFF was added), IL-6 was 454.47 pg / mL, indicating that BAFF stimulation activated B cells and enhanced IL-6 secretion.

[0232] On the other hand, the values ​​in the mangiferin 8a administration group and the norathyriol administration group were 71.52 pg / mL and 61.39 pg / mL, respectively.

[0233] As described above, it was found that administration of mangiferin 8a and norathyriol significantly suppresses BAFF-stimulated IL-6 secretion. As a result, it can be said that excessive IL-6 secretion is suppressed and allergic diseases are improved.

[0234] Example 39: Inhibitory effect on Th1 cell activation in an inflammation-induced mouse model. A 0.1 mL mixture of equal parts Freund's Complete Ajuvant and Bovine type 2 collagen was administered to 6-week-old male DBA / 1J mice (Shimizu Experimental Materials) (day 0 of the study). After 21 days, 0.1 mL of the mixture was injected into the DBA / 1J mice again for secondary immunization. After the secondary immunization, the mice were orally administered 10 mg / kg of mangiferin 8a and 10 mg / kg of norathyriol daily for 20 days. After 20 days, thymus glands were harvested from the mice and stained with anti-CD4 and anti-IFNγ antibodies, which are Th1 cell markers. The expression of IFNγ (CD4 positive) was measured using a BD LSRFortessa.

[0235] The results are shown in Figure 44. In each figure, the horizontal axis represents the expression level of IFNγ (CD4 positive), and the vertical axis represents the cell number. In addition, the solid line in the panel represents the control without inflammation induction, the dashed line represents the inflammation-induced group (vehicle), and the dotted line represents the inflammation-induced group to which each compound was administered. Compared to the control without inflammation induction, the vehicle group showed a significant increase in IFNγ expression, indicating the activation of Th1 cells. In the mangiferin 8a-administered group (Figure 44(a)) and the norathyriol-administered group (Figure 44(b)), the IFNγ expression level was significantly reduced compared to the vehicle group, reaching almost the same level as the control. In other words, it was found that mangiferin 8a and norathyriol suppressed the activation of Th1 cells in inflammation model mice.

[0236] Example 40: Inhibitory effect on Th2 cell activation in an inflammation-induced mouse model. 0.1 mL of an equal mixture of Freund's Complete Ajuvant and Bovine type 2 collagen was administered to 6-week-old male DBA / 1J mice (Shimizu Experimental Materials) (day 0 of the study). 21 days later, 0.1 mL of the mixture was injected again into the DBA / 1J mice for secondary immunization. After the secondary immunization, mangiferin 8a (10 mg / kg) and norathyriol (10 mg / kg) were orally administered to the mice daily for 20 days. 20 days later, thymus glands were collected from the mice and stained with anti-CD4 and anti-IL-4 antibodies, which are Th2 cell markers. IL-4 (CD4 positive) expression was measured using a BD LSRFortessa.

[0237] The results are shown in Figure 45. In each figure, the horizontal axis represents the expression level of IL-4 (CD4 positive), and the vertical axis represents the cell count. In addition, the solid line in the panel represents the control without inflammation induction, the dashed line represents the inflammation-induced group (vehicle), and the dotted line represents the inflammation-induced group to which each compound was administered. Compared to the control without inflammation induction, the vehicle group showed a significant increase in IL-4 expression, indicating the activation of Th2 cells. In the mangiferin 8a-administered group (Figure 45(a)) and the norathyriol-administered group (Figure 45(b)), the IL-4 expression level was significantly reduced compared to the vehicle group, reaching almost the same level as the control. In other words, it was found that mangiferin 8a and norathyriol suppressed the activation of Th2 cells in the inflammation model mice.

[0238] Example 41: Inhibitory effect on Th17 cell activation in an inflammation-induced mouse model. 0.1 mL of an equal mixture of Freund's Complete Ajuvant and Bovine type 2 collagen was administered to 6-week-old male DBA / 1J mice (Shimizu Experimental Materials) (day 0 of the study). Twenty-one days later, 0.1 mL of the mixture was injected again into the DBA / 1J mice for secondary immunization. After the secondary immunization, mangiferin 8a (10 mg / kg) and norathyriol (10 mg / kg) were orally administered to the mice daily for 20 days. After 20 days, thymus glands were harvested from the mice and stained with anti-CD4 and anti-IL-17A antibodies, which are Th17 cell markers. IL-17A (CD4 positive) expression was measured using a BD LSRFortessa.

[0239] The results are shown in Figure 46. In each figure, the horizontal axis represents the expression level of IL-17A (CD4 positive), and the vertical axis represents the cell count. In addition, the solid line in the panel represents the control without inflammation induction, the dashed line represents the inflammation-induced group (vehicle), and the dotted line represents the inflammation-induced group to which each compound was administered. Compared to the control without inflammation induction, the vehicle group showed a significant increase in IL-17A expression, indicating the activation of Th17 cells. In the mangiferin 8a-administered group (Figure 46(a)) and the norathyriol-administered group (Figure 46(b)), the IL-17A expression level was significantly reduced compared to the vehicle group, reaching almost the same level as the control. In other words, it was found that mangiferin 8a and norathyriol suppressed the activation of Th17 cells in inflammation model mice.

[0240] Example 42: Effect of promoting Treg cell activation in an inflammation-induced mouse model. A 0.1 mL mixture of equal parts Freund's Complete Ajuvant and Bovine type 2 collagen was administered to 6-week-old male DBA / 1J mice (Shimizu Experimental Materials) (day 0 of the study). Twenty-one days later, 0.1 mL of the mixture was injected again into the DBA / 1J mice for secondary immunization. After the secondary immunization, the mice were orally administered 10 mg / kg of mangiferin 8a and 10 mg / kg of norathyriol daily for 20 days. After 20 days, thymuses were harvested from the mice and stained with Treg cell markers, anti-CD4, anti-CD25, and anti-Foxp3 antibodies. Expression of Foxp3 (CD4 positive, CD25 positive) was measured using a BD LSRFortessa.

[0241] The results are shown in Figure 47. In each figure, the horizontal axis represents the expression level of Foxp3 (CD4 positive, CD25 positive), and the vertical axis represents the cell number. In addition, the solid line in the panel represents the control without inflammation induction, the dashed line represents the inflammation-induced group (vehicle), and the dotted line represents the inflammation-induced group plus administration of each compound. Compared to the control without inflammation induction, Foxp3 expression was significantly reduced in the vehicle group, indicating that Treg cell activity was suppressed. In the mangiferin 8a-administered group (Figure 47(a)) and the norathyriol-administered group (Figure 47(b)), Foxp3 expression was slightly increased compared to the vehicle group. In other words, it was found that mangiferin 8a and norathyriol promote the activation of Treg cells in inflammation model mice.

[0242] Example 43: Cell proliferation inhibitory effect on B cells The inhibitory effect of compounds on B cell proliferation was investigated using mouse B cells.

[0243] B cells collected from mice were cultured for one day in RPMI 1640 medium. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate B cells. After one day of culture, 10 μg / mL LPS (lipopolysaccharide) was added to each B cell, and the cells were cultured for three days. After three days of culture, the number of viable cells was measured using the trypan blue dye method. The results are shown in Figure 48. LPS was used as an allergic inflammation inducer.

[0244] Referring to Figure 48, the horizontal axis indicates the treatment with each compound, and the vertical axis indicates the number of cells (1 x 10 4 The cells / mL are shown. A group containing only 0.5% DMSO in PBS, which was used to dissolve the reagent (compound), was used as a control. Groups administered with 10 μg / mL of LPS are called the LPS-administered group, groups administered with a combination of LPS and mangiferin 8a are called the mangiferin 8a-administered group, and groups administered with a combination of LPS and norathyriol are called the norathyriol-administered group.

[0245] The number of control cells was 1.66 x 10 4 cells / mL in the LPS-treated group, whereas the 4 It can be seen that B cells were activated by stimulation with LPS at 1.16 × 10 cells / mL and cell proliferation was enhanced. 4 cells / mL, 1.16×10 4 cells / mL.

[0246] As described above, it was found that administration of mangiferin 8a and norathyriol significantly inhibited LPS-stimulated B cell proliferation.

[0247] Example 44: Cell proliferation inhibitory effect on macrophages The inhibitory effect of compounds on macrophage cell proliferation was investigated using mouse macrophages.

[0248] Macrophages collected from mice were cultured in RPMI 1640 medium for one day. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate macrophages. After one day of culture, 10 μg / mL LPS was added to each macrophage, and the cultures were then cultured for three days. After three days of culture, the viable cell count was measured using the trypan blue dye method. The results are shown in Figure 49. LPS was used as an allergic inflammation inducer.

[0249] Referring to FIG. 49, the horizontal axis represents the treatment with each compound, and the vertical axis represents the number of cells (1×10 4 The cells / mL are shown. A group containing only 0.5% DMSO in PBS, which was used to dissolve the reagent (compound), was used as a control. Groups administered with 10 μg / mL of LPS are called the LPS-administered group, groups administered with a combination of LPS and mangiferin 8a are called the mangiferin 8a-administered group, and groups administered with a combination of LPS and norathyriol are called the norathyriol-administered group.

[0250] The number of control cells was 10.65 x 10 4 cells / mL in the LPS-treated group, whereas the 4 It can be seen that macrophages were activated by stimulation with LPS at 8.5 × 10 cells / mL and cell proliferation was enhanced. 4 cells / mL, 7.5×10 4 cells / mL.

[0251] As described above, it was found that administration of mangiferin 8a and norathyriol significantly inhibited LPS-stimulated macrophage cell proliferation.

[0252] Example 45: Inhibitory effect on differentiation into mature B cells B cells collected from mice were cultured in RPMI 1640 medium for 1 day. Subsequently, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate B cells. After 1 day of culture, 10 μg / mL LPS was added to each B cell, and the cells were then cultured for 10 days. After 10 days of culture, the cells were stained with anti-IgM and anti-IgD antibodies, which are B cell markers, and the expression of IgM and IgD was measured using BD LSRFortessa. Note that IgM-negative and IgD-negative indicate pre-B cells, IgM-positive and IgD-negative indicate immature B cells, and IgM-positive and IgD-positive indicate mature B cells.

[0253] The results are shown in Figures 50 and 51. In both figures, the horizontal axis represents the expression level of IgM, and the vertical axis represents the expression level of IgD. In the control group (Figure 50(a)) to which no compound or LPS was added, the IgM-negative / IgD-negative population was 96.7%, the IgM-positive / IgD-negative population was 1.91%, and the IgM-positive / IgD-positive population was 0.239%, whereas in the LPS-added group (Figure 50(b)), the IgM-negative / IgD-negative population was 36.6%, the IgM-positive / IgD-negative population was 41.8%, and the IgM-positive / IgD-positive population was 20.7%, demonstrating differentiation into mature B cells.

[0254] In the mangiferin 8a-treated group (Figure 51(c)), the IgM-negative IgD-negative population was 97.6%, the IgM-positive IgD-negative population was 1.82%, and the IgM-positive IgD-positive population was 0.355%. In the norathyriol-treated group (Figure 51(d)), the IgM-negative IgD-negative population was 97.7%, the IgM-positive IgD-negative population was 2.14%, and the IgM-positive IgD-positive population was 0.065%, showing a significant decrease in the proportion of mature B cells with both compounds.

[0255] That is, it was found that administration of mangiferin 8a and norathyriol inhibits the differentiation of pre-B cells into mature B cells in allergic inflammation caused by LPS.

[0256] Example 46: Inhibitory effect on plasma cell differentiation B cells collected from mice were cultured for one day in RPMI 1640 medium. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate B cells. After one day of culture, 10 μg / mL LPS was added to each B cell, and the cells were cultured for 10 days. After 10 days of culture, the cells were stained with anti-CD138 antibody, a plasma cell marker, and CD138 expression was measured using BD LSRFortessa.

[0257] The results are shown in Figure 52. In each figure, the horizontal axis represents the expression level of CD138, and the vertical axis represents the cell count. The solid line in each panel represents the control group containing neither LPS nor any compound, the dashed line represents the group containing 10 μg / mL of LPS, and the dotted line represents the group containing 10 μg / mL of LPS and each compound. Compared with the control group containing no compound or LPS, the LPS-treated group showed a significant increase in CD138 expression. The mangiferin 8a-treated group (Figure 52(a)) and the norathyriol-treated group (Figure 52(b)) showed a significant decrease in CD138 expression compared with the LPS-treated group, reaching levels similar to those of the control group. This indicates that administration of mangiferin 8a and norathyriol inhibits plasma cell differentiation during LPS-induced allergic inflammation.

[0258] Example 47: Inhibitory effect on macrophage activation Monocytes collected from mice were cultured in RPMI 1640 medium for one day. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate monocytes. After one day of culture, 10 μg / mL LPS was added, and the cells were cultured for 10 days. After 10 days of culture, the cells were stained with anti-CD11b antibody and anti-F4 / 80 antibody, which are macrophage markers, and the expression of CD11b and F4 / 80 was measured using BD LSRFortessa. Note that CD11b-positive and F4 / 80-positive indicate activated macrophages.

[0259] The results are shown in Figures 53 and 54. In both figures, the horizontal axis represents the expression level of CD11b, and the vertical axis represents the expression level of F4 / 80. In the control group (Figure 53(a)) without the addition of compounds (mangiferin 8a and norathyriol) or LPS, the CD11b-positive F4 / 80-positive population was 6.38%, while in the LPS-added group (Figure 53(b)), the CD11b-positive F4 / 80-positive population was 26.8%, indicating an increase in activated macrophages.

[0260] In the mangiferin 8a-treated group (Figure 54(c)), the CD11b-positive F4 / 80-positive population was 21.2%, and in the norathyriol-treated group (Figure 54(d)), the CD11b-positive F4 / 80-positive population was 11.6%, showing a significant decrease in the proportion of activated macrophages with both compounds.

[0261] That is, it was found that administration of mangiferin 8a and norathyriol suppressed macrophage activation in allergic inflammation caused by LPS.

[0262] Example 48: Inhibitory effect on M1 macrophage activation Monocytes collected from mice were cultured in RPMI 1640 medium for one day. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to other monocytes. After one day of culture, 10 μg / mL LPS was added to each monocyte, and the cells were then cultured for 10 days. After 10 days of culture, the cells were stained with anti-CD11b antibody, anti-F4 / 80 antibody, which are macrophage markers, and anti-CD80 antibody, which is an M1 macrophage marker, and the expression of CD80 (CD11b positive and F4 / 80 positive) was measured using a BD LSRFortessa.

[0263] The results are shown in Figure 55. In each figure, the horizontal axis represents the expression level of CD80, and the vertical axis represents the cell count. The solid line in each panel represents the control (no LPS or compound), the dashed line represents the group containing 10 μg / mL of LPS, and the dotted line represents the group containing 10 μg / mL of LPS and each compound. Compared with the control (no compound or LPS), the LPS-treated group showed significantly increased CD80 expression. The mangiferin 8a-treated group (Figure 55(a)) and the norathyriol-treated group (Figure 55(b)) showed significantly decreased CD80 expression compared with the LPS-treated group, reaching levels comparable to those of the control. This indicates that administration of mangiferin 8a and norathyriol suppressed M1 macrophage activation in LPS-induced allergic inflammation.

[0264] Example 49: Inhibitory effect of compounds on NIK activity in B cells stimulated with LPS Spleens were collected from 6-week-old male Balb / c mice, and B cells were isolated. 2 The control was a dish containing 100 mm 2 After culturing for 1 day, 10 μg / mL LPS was added and the resulting culture was incubated for 1 hour. This was designated "10 μg / mL LPS." 2 After seeding on a dish and culturing for one day, 10 μM mangiferin 8a and 10 μM norathyriol were added to each B cell. After 23 hours, 10 μg / mL LPS was added to each B cell, and then the cells were cultured for one hour. The untreated cells were used as a "control." All the cells were incubated at 37°C and 5% CO. 2 The cells were cultured under the conditions.

[0265] Proteins were extracted from the cell lysate and used as samples. Each sample was subjected to SDS-PAGE, transferred to a PVDF membrane, and assayed using anti-phospho-NIK antibody, anti-NIK antibody, anti-NF-κB p52 antibody, anti-NF-κB p65 antibody, and anti-Lamin antibody.

[0266] The results of immunoblotting are shown in Figure 56. The reagents (compounds) shown horizontally are "Control," "10 µg / mL LPS," "10 µg / mL LPS + 10 µM mangiferin 8a," and "10 µg / mL LPS + 10 µM norathyriol."

[0267] The vertical axis indicates the type of antibody, specifically, anti-phospho-NIK antibody (denoted as "Phospho-NIK"), anti-NIK antibody (denoted as "NIK"), anti-NF-κBp52 antibody (denoted as "NF-κBp52nuclear"), anti-NF-κBp65 antibody (denoted as "NF-κBp65nuclear"), and anti-Lamin antibody (denoted as "Lamin").

[0268] In the photograph of the anti-NIK antibody, no decrease in the intensity of the NIK band was observed compared to the control. In the case of the anti-phospho-NIK antibody, at 10 μg / mL LPS, it increased compared to the control. This indicates that the addition of LPS activates NIK and enhances the differentiation and activation of B cells. On the other hand, in the case of the anti-phospho-NIK antibody, the immunoblotting results of the samples from the mangiferin 8a-administered group and the norathyriol-administered group became fainter. Therefore, it can be said that mangiferin 8a and norathyriol inhibit the phosphorylation of NIK.

[0269] Next, we will look at the anti-NF-κBp52 antibody (referred to as "NF-κBp52nuclear"), anti-NF-κBp65 antibody (referred to as "NF-κBp65nuclear"), and anti-Lamin antibody (referred to as "Lamin") against intranuclear substances. Lamin was present regardless of the compound, but it was confirmed that intranuclear NF-κBp52 was fainter in the mangiferin 8a-administered group and the norathyriol-administered group compared to 10 μg / mL LPS. In addition, intranuclear NF-κBp65 was also reduced (lighter shade) in all compounds compared to 10 μg / mL LPS.

[0270] Lamin is a fibrous protein that maintains structure and regulates transcription within the cell nucleus, and is detected as an internal standard (loading control) for nuclear proteins. Therefore, when the loading control for nuclear proteins is detected in all samples, the addition of each compound indicates that NF-κB p65 and NF-κB p52 are absent or present in very small amounts within the nucleus. In other words, mangiferin 8a and norathyriol can be said to be NIK inhibitors.

[0271] Example 50: Inhibitory effect on TNFα secretion in B cells Using mouse B cells, the inhibitory effect of compounds on TNFα secretion upon stimulation with LPS was examined.

[0272] Mouse B cells were cultured in RPMI 1640 medium for 1 day. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate B cells, and after culturing for 1 day, 10 μg / mL LPS was added to each B cell, and the cells were cultured for 2 days.

[0273] Therefore, four types of samples were prepared: an untreated "Control," 10 μg / mL LPS and 10 μM mangiferin 8a ("10 μg / mL LPS + 10 μM mangiferin 8a"), 10 μg / mL LPS and 10 μM norathyriol ("10 μg / mL LPS + 10 μM norathyriol"), and 10 μg / mL LPS only ("10 μg / L LPS").

[0274] After culturing these samples for 2 days, the culture supernatants were collected and the amount of TNFα secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse TNFα ELISA kit (R&D).

[0275] The results are shown in Figure 57. The horizontal axis represents the sample group, and the vertical axis represents the amount of TNFα secreted. In the control group, TNFα was 15.13 pg / mL, while in the 10 μg / mL LPS group, it was 296.31 pg / mL, indicating that LPS stimulation activated B cells and enhanced TNFα secretion. In the mangiferin 8a-administered group and the norathyriol-administered group, it was 59.31 pg / mL and 64.13 pg / mL, respectively.

[0276] As described above, it was found that administration of mangiferin 8a and norathyriol significantly suppressed TNFα secretion stimulated by LPS.

[0277] Example 51: Inhibitory effect on IL-6 secretion in B cells Using mouse B cells, the inhibitory effect of compounds on IL-6 secretion upon stimulation with LPS was investigated.

[0278] Mouse B cells were cultured in RPMI 1640 medium for 1 day. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate B cells, and after culturing for 1 day, 10 μg / mL LPS was added to each B cell, and the cells were cultured for 2 days.

[0279] Therefore, four types of samples were prepared: an untreated "Control," 10 μg / mL LPS and 10 μM mangiferin 8a ("10 μg / mL LPS + 10 μM mangiferin 8a"), 10 μg / mL LPS and 10 μM norathyriol ("10 μg / mL LPS + 10 μM norathyriol"), and 10 μg / mL LPS only (referred to as "10 μg / L LPS").

[0280] After culturing these samples for 2 days, the culture supernatants were collected and the amount of IL-6 secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse IL-6 ELISA kit (R&D).

[0281] The results are shown in Figure 58. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-6 secretion. In the control group, IL-6 was 9.46 pg / mL, while in the 10 μg / mL LPS group, it was 246.13 pg / mL, indicating that LPS stimulation activated B cells and enhanced IL-6 secretion. In the mangiferin 8a-administered group and the norathyriol-administered group, it was 54.13 pg / mL and 56.13 pg / mL, respectively.

[0282] As described above, it was found that administration of mangiferin 8a and norathyriol significantly suppressed LPS-stimulated IL-6 secretion.

[0283] Example 52: Inhibitory effect on TNFα secretion in macrophages Using mouse macrophages, the inhibitory effect of compounds on TNFα secretion upon stimulation with LPS was investigated.

[0284] Mouse macrophages were cultured in RPMI 1640 medium for 1 day. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to different macrophages, and after culturing for 1 day, 10 μg / mL LPS was added to each macrophage, and the macrophages were cultured for 2 days.

[0285] Therefore, four types of samples were prepared: an untreated "Control," 10 μg / mL LPS and 10 μM mangiferin 8a ("10 μg / mL LPS + 10 μM mangiferin 8a"), 10 μg / mL LPS and 10 μM norathyriol ("10 μg / mL LPS + 10 μM norathyriol"), and 10 μg / mL LPS only (referred to as "10 μg / L LPS").

[0286] After culturing each sample for 2 days, the culture supernatant was collected and the amount of TNFα secreted was measured by enzyme-linked immunosorbent assay (ELISA) using a mouse TNFα ELISA kit (R&D).

[0287] The results are shown in Figure 59. The horizontal axis represents the sample group, and the vertical axis represents the amount of TNFα secreted. In the control group, TNFα was 24.11 pg / mL, while in the 10 μg / mL LPS group, it was 421.13 pg / mL, indicating that LPS stimulation activated macrophages and enhanced TNFα secretion. In the mangiferin 8a-administered group and the norathyriol-administered group, it was 65.13 pg / mL and 68.13 pg / mL, respectively.

[0288] As described above, it was found that administration of mangiferin 8a and norathyriol significantly suppressed TNFα secretion stimulated by LPS.

[0289] Example 53: Inhibitory effect on IL-6 secretion in mouse macrophages The inhibitory effect of compounds on IL-6 secretion upon stimulation with LPS was investigated using mouse macrophages.

[0290] Mouse macrophages were cultured in RPMI 1640 medium for 1 day. Then, 10 μM mangiferin 8a and 10 μM norathyriol were added to separate macrophages. After culturing for 1 day, 10 μg / mL LPS (lipopolysaccharide) was added to each macrophage, and the cells were cultured for 2 days. After culturing for 2 days, the culture supernatant was collected, and the amount of IL-6 secreted was measured by enzyme-linked immunosorbent assay (ELISA). This measurement was performed using a mouse IL-6 ELISA kit (R&D).

[0291] The results are shown in Figure 60. The horizontal axis represents the sample group, and the vertical axis represents the amount of IL-6 secretion. In the control group, IL-6 was 13.13 pg / mL, while in the 10 μg / mL LPS group, it was 321.13 pg / mL, indicating that LPS stimulation activated macrophages and enhanced IL-6 secretion. In the mangiferin 8a-administered group and the norathyriol-administered group, the levels were 69.16 pg / mL and 64.13 pg / mL, respectively.

[0292] As described above, it was found that administration of mangiferin 8a and norathyriol significantly suppressed LPS-stimulated IL-6 secretion.

[0293] p52 and p65 are inflammatory signals, and when these substances translocate into the nucleus, they are thought to regulate the expression of pro-inflammatory or anti-inflammatory proteins. Therefore, inhibiting p52 nuclear translocation is thought to reduce the likelihood of inflammation, which is consistent with the results of the Examples shown in Figures 1-60. Furthermore, activation of the NIK / NF-κB p52 pathway and the NIK / NF-κB p65 pathway by BAFF and other factors is thought to be involved in B cell differentiation, B cell activation and antibody production, T cell activation, and macrophage activation, which are associated with allergic diseases. In other words, inhibiting these pathways is thought to suppress B cell differentiation and antibody production, promote dedifferentiation of plasma cells into immature B cells, and suppress T cell and macrophage activation, which is consistent with the Examples shown in Figures 1-60.

[0294] The pharmaceutical composition for ameliorating allergic diseases according to the present invention can be a pharmaceutical composition that is useful as a selective NIK inhibitor for allergic diseases caused by activation of NF-κB p52 and NF-κB p65.

Claims

1. A pharmaceutical composition for improving allergic diseases, containing as an active ingredient at least one compound selected from the group consisting of mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)), which have a xanthone skeleton.

2. A pharmaceutical composition for improving an allergic disease according to claim 1, wherein the allergic disease is an allergic disease associated with overexpression of BAFF.

3. A pharmaceutical composition for ameliorating an allergic disease according to claim 1, wherein the allergic disease is an allergic disease involving NF-κB activation.

4. A pharmaceutical composition for improving allergic diseases described in any one of claims 1 to 3, wherein the allergic disease is at least one of bronchial asthma, atopic dermatitis, hay fever, allergic rhinitis, food allergy, metal allergy, drug allergy, anaphylaxis, urticaria, allergic conjunctivitis, allergic bronchitis, and contact dermatitis.

5. An NIK inhibitor having as an active ingredient at least one compound selected from the group consisting of mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)), which have a xanthone skeleton.

6. The NIK inhibitor according to claim 5, which suppresses differentiation of plasma cells.

7. The NIK inhibitor according to claim 5, which dedifferentiates plasma cells into B cells.

8. The NIK inhibitor according to claim 5, which inhibits the proliferation of B cells.

9. The NIK inhibitor according to claim 5, which inhibits the proliferation of macrophages.

10. The NIK inhibitor according to claim 5, which suppresses the activation of macrophages.

11. The NIK inhibitor according to claim 5, which suppresses the activation of Th1 cells, Th2 cells, and Th17 cells.

12. The NIK inhibitor according to claim 5, which regulates the activation of Treg cells.

13. The NIK inhibitor according to claim 5, which suppresses the production of TNFα, IL-6, BAFF, IL-4, IL-5, IL-17 and TSLP.

14. A processed food containing at least one compound selected from the group consisting of mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)), which have a xanthone skeleton.

15. A pharmaceutical composition for improving allergic diseases according to claim 1, wherein the active ingredient is norathyriol and the allergic disease is atopic dermatitis.

16. A pharmaceutical composition for improving allergic diseases according to claim 1, wherein the active ingredient is norathyriol or mangiferin 8a and the allergic disease is atopic rhinitis.

17. A pharmaceutical composition for improving allergic diseases according to claim 1, wherein the active ingredient is norathyriol or mangiferin 8a and the allergic disease is bronchial asthma.

18. A pharmaceutical composition for improving allergic diseases according to claim 1, wherein the active ingredient is norathyriol or mangiferin 8a and the allergic disease is food allergy.

19. A pharmaceutical composition for improving allergic diseases according to claim 1, wherein the active ingredient is norathyriol or mangiferin 8a and the allergic disease is hay fever.